



Planet Depos®
We Make It *Happen™*

Transcript of James Naismith, Ph.D.

Date: June 13, 2026

Case: Merck Sharp & Dohme LLC -v- Halozyme Inc. (PTAB)

Planet Depos

Phone: 888.433.3767

Email: transcripts@planetdepos.com

www.planetdepos.com

Halozyme EX2304
Merck v. Halozyme
PGR2025-00042

1 UNITED STATES PATENT AND TRADEMARK OFFICE

2 -----
3 BEFORE THE PATENT TRIAL AND APPEAL BOARD
4 -----

5 MERCK SHARP & DOHME LLC,
6 Petitioner,

7 v.

8 HALOZYME, INC.,
9 Patent Owner.

10 -----
11 Case Nos.: PGR2025-00042 Patent Nos.: 12,037,618
12 PGR2025-00046 12,091,692
13 PGR2025-00052 12,264,345
14 -----

15 VIDEO DEPOSITION OF JAMES NAISMITH, Ph.D.

16 Saturday, June 13, 2026
17 12:41 p.m. (BST)

18 The Randolph Hotel
19 Beaumont Street
20 Oxford, OX1 2LN
21 United Kingdom
22

23 Job No.: 638140
24 Court Reporter:
25 Chanelle Malliff, CLR, ACR, QRR2*

A P P E A R A N C E S

FOR THE PETITIONER:

SIDLEY AUSTIN LLP

1501 K Street NW
Washington, DC 20005
(202) 736-8914

By: Jeffrey P. Kushan (In person)
jkushan@sidley.com

Dr. Amy L. Mahan (Via Zoom)
amahan@sidley.com

Chelsea Himes (Via Zoom)
chimes@sidley.com

FOR THE PATENT OWNER: (all via Zoom)

QUINN EMANUEL URQUHART & SULLIVAN LLP

111 Huntington Avenue, Suite 520
Boston, MA 02199
(617) 712-7100

By: Lauren Martin
laurenmartin@quinnemanuel.com

Elliot Choi
elliottchoi@quinnemanuel.com

Zach Summers
zachsummers@quinnemanuel.com

A P P E A R A N C E S

(continued)

FOR THE PATENT OWNER: (all via Zoom)

STERNE, KESSLER, GOLDSTEIN & FOX PLLC
1101 K Street NW, 10th Floor
Washington DC 20005
(202) 772-8508

By: Eldora L. Ellison
eellison@sternekeessler.com

Tray Powers
tpowers@sternekeessler.com

Also Present:

(In person) Wendy Viner,
Videographer, Planet Depos

(Via Zoom) Josh Mack,
Executive Director, Patent Litigation
Counsel at Halozyne, Inc.

(Via Zoom) Aubrey Haddach, Halozyne

C O N T E N T S

Deponent	Page
DR. JAMES NAISMITH (sworn)	6
Examination by Ms. Martin	6

E X H I B I T I N D E X
(Previously marked)

No.	Description	Page
Exhibit 1133	Naismith Declaration PGR2025-00004, US Patent No. 12,018,298	10
Exhibit 1133	Naismith Declaration PGR2025-00046, US Patent No. 12,091,692	11
Exhibit 1001	US Patent No. 12,018,298, ... Date of Patent: June 25, 2024	12
Exhibit 1001	US Patent No. 12,091,692, ... Date of Patent: Sep. 17, 2024	13
Exhibit 1026	Common disclosure	59

1 Saturday, June 13, 2026

2 P R O C E E D I N G S

3 (On the record at 12:41 p.m.)

4 VIDEOGRAPHER: Here begins media 1 in the 12:41:07
5 videotaped deposition Dr. James Naismith, in the 12:41:09
6 matter of Merck Sharp & Dohme LLC v Halozyne, Inc. in 12:41:11
7 the United States Patent and Trademark Office, case 12:41:16
8 numbers PGR2025-0042, PGR2025-0046 and PGR2025-0052. 12:41:19

9 Today's date is June 13, 2026 and the time is 12:41:37
10 12:41 p.m. This video deposition is taking place at 12:41:41
11 The Randolph Hotel, Beaumont Street, Oxford, UK. 12:41:46

12 The videographer today is Wendy Viner on 12:41:51
13 behalf of Planet Depos. 12:41:54

14 Could I ask counsel to please identify 12:41:56
15 themselves and state whom they represent, beginning 12:41:57
16 with the attorney in the room, followed by our Zoom 12:41:59
17 participants. 12:42:03

18 MR. KUSHAN: Jeff Kushan from Sidley Austin, 12:42:09
19 representing Merck Sharp & Dohme LLC. 12:42:11

20 MS. MARTIN: Lauren Martin from 12:42:21
21 Quinn Emanuel, representing Halozyne. 12:42:22

22 MR. KUSHAN: Can we also -- you can probably 12:42:29

1 get all the names of the rest of the people attending 12:42:31
2 from the Zoom. 12:42:33

3 VIDEOGRAPHER: Of course. No worries. 12:42:35

4 Our court reporter today is Chanelle Malliff 12:42:36
5 on behalf of Planet Depos. 12:42:38

6 Will the court reporter please swear in the 12:42:40
7 witness and we can proceed. 12:42:42

8 DR. JAMES NAISMITH 12:42:45

9 having duly sworn to tell the truth, 12:42:55
10 was examined and testified as follows: 12:42:55

11 EXAMINATION 12:43:01

12 BY MS. MARTIN: 12:43:01

13 Q. Good afternoon, Dr. Naismith. 12:43:03

14 A. Good afternoon. I realize it's very early in 12:43:05
15 the morning for you, so thank you for being flexible. 12:43:06

16 Q. No worries. Thank you for making yourself 12:43:09
17 available on a Saturday. We really appreciate that. 12:43:11

18 All right, so under the Patent Trial and 12:43:17
19 Appeal Board standing order in this matter 12:43:20

20 I'm obligated to give you the following instruction, 12:43:23
21 which I'm going to read: 12:43:26

22 "You must ask me, the deposing counsel, 12:43:29

1 rather than your own counsel for any clarifications,
2 definitions or explanations of any words, questions
3 or documents presented during the cross-examination."

12:43:31

12:43:34

12:43:38

4 Do you understand that instruction?

12:43:44

5 A. Yes, I do.

12:43:45

6 Q. Okay, great. Who is present with you in the
7 room right now?

12:43:46

12:43:49

8 A. So opposite me is the videographer. Opposite
9 and to the right is the court reporter. And to my
10 right, right of my eye line, is Mr. Kushan.

12:43:50

12:43:53

12:43:57

11 Q. Is there anything open on your computer
12 besides Zoom?

12:44:05

12:44:06

13 A. It isn't my computer that is being used here.
14 My computer is in my bag, not here.

12:44:07

12:44:09

15 Q. Okay. So you were provided a computer by
16 the -- by somebody at Planet Depos?

12:44:13

12:44:16

17 A. I'm looking to check. It's their computer
18 but yeah, they say yes it's their computer.

12:44:22

12:44:24

19 Q. Oh okay, got it. Got it. So did you bring
20 any materials with you besides the exhibits that
21 we've talked about?

12:44:26

12:44:36

12:44:38

22 A. No.

12:44:44

1 Q. Have you marked anything on any of those
2 exhibits?

3 A. No. They were provided to me this morning,
4 brought in by Mr. Kushan, so I haven't touched them.

5 Q. Okay. What did you do to prepare for the
6 deposition today?

7 A. I reread my declarations in the three
8 matters. I looked back through the patents, the
9 disclosure -- the common disclosure. I looked again
10 at the declarations, particularly from Hecht, Simpson
11 and Petsko. And I looked again through my
12 deposition -- um, and scanned through my own
13 deposition and my previous declarations for I think
14 matter 4 but I would say "the '600 patent". So if
15 that's the wrong thing, my apologies.

16 Q. Who did - did you meet with anyone to prepare
17 for this deposition?

18 A. Yes, I did.

19 Q. Who did you meet with?

20 A. I met with Mr. Kushan and, I forget his
21 second name but Leif and Amy from Sidley Austin.

22 Q. For how long did you meet with them?

1 A. Mr. Kushan and I spent about five hours 12:46:03
2 yesterday evening in Oxford with Amy -- and 12:46:06
3 I forget -- Mahan I think online, and I can't 12:46:10
4 remember Leif's second name but they were online for 12:46:14
5 most but not all of that time. 12:46:17

6 Q. And was that the only meeting that you had 12:46:19
7 with counsel to prepare for this deposition? 12:46:20

8 A. No, we'd had -- when I was told there would 12:46:23
9 be -- there would be a deposition in this matter, we 12:46:26
10 had a couple of Zoom meetings online to discuss what 12:46:29
11 timing arrangements and also what the scope would be, 12:46:36
12 so where I should focus my attention. 12:46:40

13 MR. KUSHAN: I'm gonna counsel the witness to 12:46:46
14 not reveal any attorney-client privileged 12:46:47
15 communications. 12:46:51

16 BY MS. MARTIN: 12:46:55

17 Q. Dr. Naismith, are you aware that the board 12:46:55
18 has issued final written decisions in some of the 12:46:57
19 PGRs? 12:47:02

20 A. Yes, I'm aware that there is a final 12:47:02
21 judgment, yes. 12:47:06

22 Q. Have you read any of the final written 12:47:10

1	decisions?	12:47:12
2	A. I read the last page, I think. I haven't	12:47:13
3	read through the document, no.	12:47:16
4	Q. Did you consider the contents of the final	12:47:24
5	written decisions in preparing your declarations in	12:47:26
6	the 42, 46 and 52 matters?	12:47:30
7	A. No, I did not.	12:47:34
8	Q. Did you consider the contents of the final	12:47:37
9	written decisions in preparing for your deposition	12:47:40
10	today?	12:47:42
11	A. No, I did not.	12:47:43
12	Q. Can you please find the matter 4 declaration,	12:47:59
13	which was in the box labeled Exhibit 1 for the '298	12:48:05
14	patent.	12:48:12
15	(Previously marked Exhibit 1133 identified.)	12:48:13
16	A. Of course. If you give me just a second.	12:48:13
17	VC TECHNICIAN: Would you like me to pull	12:48:22
18	that up on the screen, Ms. Martin?	12:48:23
19	MS. MARTIN: Yeah, that would be great.	12:48:26
20	A. So I have, just to check we're on the same	12:48:27
21	one, PGR2025-00004, US Patent ends in '298; is that	12:48:29
22	correct?	12:48:36

1 BY MS. MARTIN:

12:48:39

2 Q. Yes, that's correct. Okay, so please keep
3 that handy. And then also please find the
4 declaration for matter 46, which is for the '692
5 patent. And that should be one of the ones that you
6 brought with you.

12:48:39

12:48:41

12:48:52

12:48:57

12:49:00

7 (Reporter clarification.)

12:49:24

8 MS. MARTIN: So the first document, the
9 declaration from matter 4, is Exhibit 1133.

12:49:26

12:49:27

10 So all of the Naismith declarations are
11 Exhibit 1133 and their respective matters.

12:49:31

12:49:33

12 So then the second document is the
13 declaration from matter 46, so that's also
14 Exhibit 1133 in the matter 46 case.

12:49:41

12:49:44

12:49:48

15 COURT REPORTER: Is the technician
16 electronically marking them or are they already
17 marked?

12:50:05

12:50:06

12:50:09

18 MR. KUSHAN: They're already marked.

12:50:10

19 COURT REPORTER: They're already marked.
20 Okay.

12:50:11

12:50:11

21 MS. MARTIN: They're already marked.

12:50:12

22 (Previously marked Exhibit 1133 identified.)

12:50:13

1	THE WITNESS: So I see I need to just correct	12:50:14
2	myself, which was when I looked at this case --	12:50:15
3	I don't know the case number but it was the '600	12:50:17
4	patent and this is the '298. But I now understand	12:50:19
5	the declarations are essentially the same.	12:50:22
6	BY MS. MARTIN:	12:50:23
7	Q. Yeah, yeah, I think the '600 was for --	12:50:24
8	I think was matter 3.	12:50:25
9	A. Yeah, it was just so that I didn't -- okay.	12:50:26
10	Q. Understood. Okay, so do you have your matter	12:50:31
11	46 declaration?	12:50:37
12	A. Yes.	12:50:38
13	Q. Okay. And then for ease of reference here,	12:50:40
14	if you could also pull out the '298 patent, which was	12:50:46
15	Exhibit 2 in the box, and that's Exhibit 1001 from	12:50:51
16	matter 4.	12:50:56
17	(Previously marked Exhibit 1001 identified.)	12:51:11
18	A. So there are three copies. Will I give one	12:51:17
19	to Mr. Kushan?	12:51:19
20	Q. Sure. Thank you.	12:51:20
21	A. So this is what is in the box and it ends in	12:51:23
22	'298; is that correct?	12:51:26

1 Q. Yes. Yes, perfect. And then if you want to 12:51:29
2 also get the '692 patent, which you should have in 12:51:36
3 the materials that Mr. Kushan provided. And that's 12:51:41
4 Exhibit 1001 from matter 46. So do you have all of 12:51:43
5 those? 12:52:08

6 (Previously marked Exhibit 1001 identified.) 12:52:08

7 A. I have four things in front of me. 12:52:09

8 Q. Perfect. Okay, so can you please turn in the 12:52:11
9 matter 46 declaration to paragraph 90? 12:52:22

10 VC TECHNICIAN: Ms. Martin, do you have a 12:52:38
11 page number, by any chance? 12:52:40

12 THE WITNESS: It begins on page 57 in my copy 12:52:56
13 in front of me, "Defined Terms ..." headed. 12:53:00

14 BY MS. MARTIN: 12:53:18

15 Q. Dr. Naismith, do you have paragraph 90? 12:53:18

16 A. Yes, I do. 12:53:22

17 Q. All right. The terms "PH20" and "modified 12:53:23
18 PH20 polypeptide" are defined in the common 12:53:30
19 disclosure, correct? 12:53:34

20 A. That's ... I said that's right. The common 12:53:35
21 disclosure defines these two terms. 12:53:38

22 Q. And if you then continue on, I think under 12:53:43

1	paragraph 90 on page 58 in your declaration, you	12:53:47
2	excerpted the paragraphs in the common disclosure	12:53:52
3	that include those definitions, is that right?	12:53:57
4	A. That's correct, I've highlighted two long	12:54:01
5	paragraphs where those are talked about and defined.	12:54:03
6	Q. And then if you go to paragraph 91, which is	12:54:09
7	on page 59. You said:	12:54:12
8	"Dr. Simpson testified at her deposition	12:54:18
9	that the first sentence in each	12:54:21
10	paragraph above (highlighted in yellow)	12:54:22
11	is the definition of each term."	12:54:25
12	Is that right?	12:54:27
13	A. That's what Dr. Simpson stated, I think in	12:54:27
14	her deposition, and I've excerpted the relevant	12:54:30
15	portion from the deposition.	12:54:33
16	Q. Okay. Can you then go back to page 58 that	12:54:42
17	has the portions from the common disclosure?	12:54:45
18	A. Yes, I have.	12:54:48
19	Q. So do you agree with Dr. Simpson that the	12:54:49
20	first sentence in each paragraph is the definition of	12:54:51
21	each of the terms?	12:54:57
22	A. It's not a complete definition. I think you	12:55:00

1 have to read the whole paragraph to get the complete
2 definition, but the first definition, the first
3 sentence, captures essential features of it. That it
4 is:

5 "... PH20 ..."

6 When it's used in the patent:

7 "... refers to a type of hyaluronidase
8 that occurs in sperm and is
9 neutral-active."

10 But there are important other parts of the
11 definition spelt out in the paragraph.

12 Q. Okay, so are you saying that the complete
13 paragraph for each of those terms is the definition?

14 A. So I said that you read -- the first sentence
15 is key but you have to read -- you read through the
16 full paragraph and it helps you clarify the
17 definition of what it is being used in the common
18 disclosure.

19 Q. So then can you turn to paragraph 100, which
20 is on pages 65 to 66?

21 A. I'm on paragraph 100.

22 Q. Okay. And then below paragraph 100, on

12:55:02

12:55:04

12:55:08

12:55:12

12:55:14

12:55:14

12:55:15

12:55:19

12:55:21

12:55:22

12:55:24

12:55:30

12:55:33

12:55:36

12:55:39

12:55:42

12:55:44

12:55:47

12:55:51

12:55:54

12:56:09

12:56:13

1 page 66, you've excerpted again that paragraph from
2 the specification that has the definition for
3 modified PH20 polypeptide?

12:56:17

12:56:21

12:56:25

4 A. I've excerpted part of that paragraph, that's
5 correct.

12:56:28

12:56:31

6 Q. And you've highlighted the second sentence in
7 that paragraph, that starts:

12:56:43

12:56:46

8 "A modified PH20 polypeptide can have up
9 to [100] (sic) amino acid
10 replacements ..."

12:56:48

12:56:52

12:56:55

11 Is that right?

12:56:56

12 A. In my declaration that has a yellow
13 highlighter for that sentence.

12:56:58

12:57:01

14 Q. All right, so let's turn back to
15 paragraph 100. Perfect. Do you see the second
16 sentence in paragraph 100?

12:57:10

12:57:11

12:57:19

17 A. It begins:

12:57:22

18 "After defining the phrase ..."

12:57:22

19 Q. Yes. So you say:

12:57:25

20 "After defining the phrase 'modified
21 PH20 polypeptide,' the common disclosure
22 explains that modified PH20 proteins

12:57:30

12:57:34

12:57:37

1	'can have up to 150 amino acid	12:57:38
2	replacements, so long as the resulting	12:57:43
3	modified PH20 polypeptide exhibits	12:57:45
4	hyaluronidase activity' (below)."	12:57:48
5	Correct?	12:57:51
6	A. Yeah, those are the words that are written in	12:57:51
7	my declaration, yes.	12:57:56
8	Q. So when you wrote the declaration, you stated	12:58:00
9	that the sentence that starts -- the sentence that	12:58:04
10	says:	12:58:10
11	"A modified PH20 polypeptide can have up to [100]	12:58:10
12	(sic) amino acid replacements ..."	12:58:14
13	That sentence appears after the phrase "modified	12:58:16
14	PH20 polypeptide" is defined; correct?	12:58:21
15	A. When you say "after" in terms of the	12:58:26
16	paragraph that is excerpted the sentence follows --	12:58:28
17	one follows the other, is that what you mean? When	12:58:32
18	you --	12:58:35
19	Q. Well you use --	12:58:35
20	A. -- say "after", I want to check.	12:58:35
21	Q. Sorry. I don't want to talk over you.	12:58:41
22	A. My apologies. My question was, when you say	12:58:43

1	"after", so the paragraph I've excerpted begins:	12:58:46
2	"As used herein, 'modified PH20	12:58:50
3	polypeptide' ... refers to a PH20	12:58:54
4	polypeptide that contains at least ..."	12:58:57
5	Blah, blah, blah, and then it goes on to	12:59:00
6	further define. But you need to read the entire	12:59:02
7	paragraph to understand the definition that's being	12:59:05
8	applied here.	12:59:07
9	Q. So I'm asking you about the phrase that you	12:59:11
10	used in your declaration, which is after defining the	12:59:14
11	phrase "modified PH20 polypeptide"?	12:59:18
12	A. Yes, so that's right, so the first sentence	12:59:22
13	begins that definition, which is the first	12:59:25
14	definition, and then you get this additional sentence	12:59:28
15	that helps you understand that definition and	12:59:30
16	clari -- so you're clear in your mind what it says.	12:59:32
17	Q. So I think we can all agree that the first	12:59:38
18	sentence:	12:59:40
19	"As used herein, 'modified PH20 polypeptide' ..."	12:59:42
20	Is the definition, right?	12:59:44
21	MR. KUSHAN: Objection, foundation.	12:59:47
22	THE WITNESS: No, I don't agree with that.	12:59:49

1 I think you have to, as I've said, read the entire
2 paragraph in this case and it clearly tells you
3 that -- it tells you at the first sentence it begins
4 what it's talking about is a concept of modified
5 polypeptide and then it gives you a clear limitation
6 to that, which says it has "up to 150 amino acid
7 replacements, so long as [it] ... exhibits
8 hyaluronidase activity". And it further begins to
9 tell you what the other amino acid replacements are
10 and can include any one or more of those
11 modifications or at least one replacement.

12 BY MS. MARTIN:

13 Q. So in your declaration when you said that
14 that sentence about the 150 replacements comes after
15 the definition, you were wrong, right?

16 A. No, I don't think I was wrong. I said that
17 that sentence is the beginning of the definition so
18 there is a definition but you have to read the whole
19 paragraph to understand what the full meaning is.
20 That's why I have excerpted the whole paragraph.

21 Q. So let's keep page 66 handy but then if you
22 can go to paragraph 109, which is on page 74?

12:59:50

12:59:54

12:59:58

13:00:02

13:00:05

13:00:09

13:00:12

13:00:15

13:00:17

13:00:23

13:00:26

13:00:27

13:00:34

13:00:35

13:00:38

13:00:43

13:00:46

13:00:49

13:00:51

13:00:53

13:01:06

13:01:09

1	A. Yes.	13:01:26
2	Q. You say in paragraph 109:	13:01:38
3	"I recognize that the definition of	13:01:40
4	'modified PH20 polypeptide' in the	13:01:42
5	common disclosure considered in	13:01:46
6	isolation does not explicitly state that	13:01:47
7	each modified PH20 polypeptide is	13:01:51
8	enzymatically active."	13:01:54
9	Correct?	13:01:57
10	A. That's correct, that's what the sentence	13:01:58
11	says.	13:02:01
12	Q. So in paragraph 109 you state that the term	13:02:07
13	"modified PH20 polypeptide" is not defined to require	13:02:10
14	enzymatic activity; correct?	13:02:15
15	MR. KUSHAN: Objection, foundation.	13:02:19
16	THE WITNESS: No, that's not what I state in	13:02:21
17	that paragraph. I said that it does not, when	13:02:23
18	considered in isolation does not explicitly state	13:02:25
19	that each modified PH20 polypeptide is enzymatically	13:02:28
20	active. And I did not base my opinion solely on	13:02:35
21	that. Instead, I pointed out that only when	13:02:38
22	I considered all the language in certain claims, and	13:02:40

1 then in conjunction with the common disclosure 13:02:42

2 I would have considered that the claims as a whole 13:02:45

3 define a set of modified PH20s that exhibit 13:02:49

4 hyaluronidase activity. 13:02:54

5 What the point I make in paragraph 109 is 13:02:55

6 that the phrase in isolation does not explicitly 13:02:57

7 state enzymatically active. I didn't base my opinion 13:03:02

8 on a single isolated phrase. 13:03:06

9 Q. Well, so you say the definition of modified 13:03:14

10 PH20 polypeptide considered in isolation. So when 13:03:17

11 you said the definition of modified PH20 polypeptide 13:03:20

12 in paragraph 109, what language from the common 13:03:23

13 disclosure were you referring to? 13:03:28

14 A. So the phrase "modified PH20 polypeptide" 13:03:31

15 appears multiple times in the common disclosure. My 13:03:34

16 point was that I didn't use simply that phrase on its 13:03:40

17 own in isolation to form my -- how I have read and 13:03:43

18 understood the patent. I set out the reasons for 13:03:47

19 my -- how I have approached this analysis in the 13:03:50

20 previous paragraphs and I said that it was important 13:03:53

21 that you had to read the entire common disclosure. 13:03:56

22 Q. That was not my question. My question was, 13:04:01

1 when you used the word "definition" in paragraph 109, 13:04:03
2 what portion -- what portion of the paragraph that 13:04:09
3 has the definition of modified PH20 were you talking 13:04:11
4 about when you said -- when you used the word 13:04:15
5 "definition" in paragraph 109? 13:04:18

6 MR. KUSHAN: Objection to form. 13:04:20

7 THE WITNESS: So what I'm talking about is 13:04:25
8 the phrase in isolation -- a definition in isolation 13:04:26
9 of modified PH20 polypeptide occurs in the common 13:04:29
10 disclosure in different places. But on its own, just 13:04:34
11 that isolated phrase, doesn't, how I understand the 13:04:38
12 requirement for enzyme activity, that I didn't base 13:04:42
13 my opinion simply in that words "modified PH20 13:04:45
14 polypeptide". 13:04:50

15 BY MS. MARTIN: 13:04:54

16 Q. Well, your sentence doesn't say -- that's not 13:04:54
17 what the sentence says. Do you agree with the 13:04:57
18 sentence that you wrote at the start of 13:05:01
19 paragraph 109: 13:05:03

20 "... that the definition of 'modified PH20 13:05:04
21 polypeptide' in the common disclosure considered in 13:05:07
22 isolation does not explicitly state that each 13:05:11

1	modified PH20 polypeptide is enzymatically active"?	13:05:14
2	A. Yes, I agreed with that, I've just said so.	13:05:18
3	That I agreed that in isolation that that phrase	13:05:20
4	where it is used doesn't on its own define --	13:05:23
5	doesn't -- sorry, doesn't explicitly state that each	13:05:27
6	is enzymatically active.	13:05:29
7	Q. And so you agree that the definition of	13:05:33
8	modified PH20 polypeptide in the common disclosure	13:05:36
9	does not explicitly state that the modified PH20	13:05:41
10	polypeptides are enzymatically active?	13:05:45
11	MR. KUSHAN: Objection to foundation.	13:05:48
12	THE WITNESS: No, my point is that in	13:05:50
13	isolation if you just cap just that isolated phrase,	13:05:53
14	it doesn't itself explicitly state that. But	13:05:57
15	I didn't use the isolated phrase to make that	13:06:00
16	definition. I said that you had --	13:06:04
17	BY MS. MARTIN:	13:06:07
18	Q. So you --	13:06:07
19	A. Sorry my -- sorry, not definition,	13:06:09
20	understanding. So the definition on its own	13:06:11
21	"modified PH20 polypeptide" in isolation is not how	13:06:12
22	I understood and read that; that you have to read the	13:06:16

1 common disclosure to fully understand what is being
2 referred to with the meaning modified PH20
3 polypeptides, and having done that I conclude that
4 they are directed to active forms of the protein.

13:06:20

13:06:24

13:06:29

13:06:32

5 Q. Can we turn back to page 66?

13:06:38

6 A. Yes.

13:06:43

7 Q. And do you agree that the first sentence:

13:06:55

8 "As used herein, 'modified PH20

13:06:58

9 polypeptide' ... refers to a PH20

13:07:02

10 polypeptide that contains at least one

13:07:04

11 amino acid modification, such as at

13:07:07

12 least one amino acid replacement as

13:07:10

13 described herein, in its sequence of

13:07:12

14 amino acids compared to a reference

13:07:15

15 unmodified PH20 polypeptide."

13:07:18

16 Do you agree that that statement from the common
17 disclosure defining modified PH20 polypeptide does
18 not include any limitation regarding activity?

13:07:20

13:07:22

13:07:26

19 MR. KUSHAN: Objection, foundation.

13:07:31

20 THE WITNESS: So what my understanding is, as

13:07:35

21 I read it and in my opinion, is that that in

13:07:37

22 isolation -- and I didn't rely on that sentence in

13:07:39

1	isolation -- that sentence in isolation does not, as	13:07:44
2	you say, state that enzymatic activity is required in	13:07:48
3	isolation. But my understanding and my opinion is	13:07:53
4	not based solely on that sentence in isolation.	13:07:56
5	BY MS. MARTIN:	13:08:06
6	Q. Can you please turn to paragraph 104?	13:08:06
7	I think it's on the next page, page 68.	13:08:10
8	A. Yes, I am there.	13:08:14
9	Q. And in paragraph 104 you state, in the third	13:08:19
10	sentence, you state that:	13:08:33
11	"PH20 is expressly defined in the common	13:08:35
12	disclosure to ..."	13:08:41
13	Sorry, it's moving on the screen. Strike that.	13:08:48
14	Let me start it again. Can you scroll back up?	13:08:48
15	A. That's why I use paper and I'm not very good	13:08:52
16	with the screen. My apologies.	13:08:55
17	Q. Fine. Okay, let me start again.	13:08:57
18	"PH20 is expressly defined in the common	13:08:59
19	disclosure to have a form a POSA would understand is	13:09:03
20	folded."	13:09:06
21	Correct?	13:09:06
22	A. That's what the sentence says, yes.	13:09:08

1 Q. So do you agree that PH20 is expressly
2 defined in the common disclosure to have a form a
3 POSA would understand is folded?

4 A. It is active, which means it is also folded.
5 So it's expressly in the disclosure as an active form
6 of the protein which is enzymatically active and
7 folded.

8 Q. But you don't use the word "active" here,
9 right, you just use the word "folded"?

10 A. That's correct, the language is different
11 because I was -- the language relates to the patent
12 I was asked to assess. But PH20 is properly
13 understood as the folded active form on the surface
14 of the sperm cell, neutral-active.

15 (Reporter clarification.)

16 Neutral-active. It's neutral-active.

17 Q. If PH20 is properly understood as folded
18 active form, then why didn't you put the word
19 "active" in that sentence in paragraph 104?

20 A. In a long report of many things I honestly
21 can't remember all my word choices but I do make it
22 clear in my conclusion and elsewhere that PH20 is the

1 express -- is an active form found on the surface of 13:10:24
2 the sperm cell. We in fact looked at that at 13:10:28
3 paragraph -- on page 58: 13:10:37

4 "As used herein, PH20 refers to a type 13:10:39
5 of hyaluronidase ...". 13:10:44

6 It goes on, sperm cell neutral-active: 13:10:46

7 "... truncated forms thereof [which] 13:10:48
8 have activity ... includes ... 13:10:48
9 variants ...". 13:10:50

10 Etc. So that's all in there. And also later on 13:10:52
11 I state the require -- as I read the claims, they're 13:10:58
12 directed to the active form of the protein. 13:11:01

13 For activity you have to have folding. 13:11:06

14 Q. So it's your testimony now that for matter 13:11:09
15 46, which is the '692 patent, that those claims are 13:11:13
16 limited to the active PH20, active modified PH20? 13:11:17

17 A. So it's my opinion, and as I set out in my 13:11:23
18 declaration and I've quite clearly stated in my 13:11:28
19 declaration, that as I read the claims they are 13:11:31
20 directed to the active mutants or modified PH -- 13:11:33
21 active modified PH20. 13:11:39

22 Now I do understand, and I set out in 13:11:41

1 paragraph 110 that claim scope is of course a matter 13:11:42
2 for the board, right. I'm not a lawyer and 13:11:46
3 I don't -- I'm not offering a legal opinion, only a 13:11:51
4 scientific one. And if the board were to enlarge the 13:11:53
5 claim scope, but I think we all agree that within the 13:11:58
6 claims are these folded active forms of the protein 13:12:02
7 then since the bulk of my opinions address written 13:12:06
8 description and enablement, my opinions are that 13:12:13
9 those things are not properly described for that 13:12:14
10 subset. So adding other subsets wouldn't change my 13:12:16
11 opinion as regards enablement and written 13:12:20
12 description. But I understand that my opinions and 13:12:24
13 how I have read the claim scope are not -- it's for 13:12:27
14 the patent board to decide how that should be read or 13:12:30
15 what the legal threshold is. 13:12:33

16 MS. MARTIN: So we agreed to limit the scope 13:12:37
17 of this deposition to claim construction. And so, 13:12:39
18 Mr. Kushan, if your witness is going to start talking 13:12:42
19 about 112 then I should be able to question him on 13:12:46
20 112, meaning that I should have more than 2 hours. 13:12:49

21 MR. KUSHAN: No. No. No. 13:12:52

22 MS. MARTIN: I feel that if we agreed to 13:12:52

1 limit it to claim construction, that's what we should
2 be doing.

3 MR. KUSHAN: He's addressing claim
4 construction. You can ask the questions focused on
5 claim construction. If you -- just continue your
6 deposition.

7 MS. MARTIN: That's fine. Just make sure
8 that we're all on the same page here.

9 BY MS. MARTIN:

10 Q. Okay, can you please turn to paragraph 43.

11 A. Paragraph 43 is on page 19 and it begins:

12 "As I explain ..."

13 Is that correct?

14 Q. Yes. Okay, so in paragraph 43, in your
15 declaration for the -- in matter 46, you say that
16 you:

17 "... read the claims as a whole as being

18 directed to modified PH20 polypeptides

19 that (i) contain an amino acid sequence

20 that satisfies the sequence identity

21 claim parameters, (ii) meet the position

22 313 substitution requirement, and (iii)

1	have folded to adopt the same tertiary	13:14:38
2	fold found in the native state of the	13:14:41
3	wild-type PH20 protein."	13:14:44
4	Correct?	13:14:46
5	A. That's what I say, yes.	13:14:47
6	Q. And that's accurate, right?	13:14:52
7	A. So it's not the complete analysis in 43, as	13:14:55
8	the first sentence begins I point you to D and E. So	13:14:58
9	in this declaration for this matter I considered --	13:15:04
10	I separated out my analysis to focus on the early	13:15:06
11	stages in the first paragraphs 43 to 48 on folding	13:15:09
12	things, understanding the folding subset, and then	13:15:15
13	I moved to consider activity in 104 to 108. And	13:15:19
14	I've produced my conclusions at the end of	13:15:22
15	paragraph 108 for how I read the claims as a whole	13:15:24
16	there. So my final conclusion about how a POSA would	13:15:27
17	read it is set there. I just split my analysis for	13:15:33
18	this particular patent into two sections.	13:15:35
19	Q. So when you included romanettes (i) through	13:15:38
20	(iii) in paragraph 43, you're saying that you instead	13:15:44
21	you intended to include a fourth romanette and you	13:15:50
22	didn't?	13:15:54

1	MR. KUSHAN: Objection to foundation.	13:15:56
2	THE WITNESS: So that's not what I'm saying.	13:15:58
3	I'm saying that I have set out my opinions as to the	13:15:59
4	full -- my full understanding of the claims in these	13:16:02
5	series of paragraphs. This is my analysis paragraph	13:16:08
6	which focuses -- this part focuses on folding.	13:16:12
7	I deal with activity later on, which I point to in E	13:16:16
8	which is the activity analysis and I end up in	13:16:22
9	paragraph 108 where I give you my conclusions and it	13:16:24
10	says a POSA would conclude.	13:16:28
11	BY MS. MARTIN:	13:16:30
12	Q. So when you say in paragraph 43 that you read	13:16:30
13	the claims as a whole as being directed to modified	13:16:33
14	PH20 polypeptides that satisfy three features --	13:16:39
15	MR. KUSHAN: Objection to foundation.	13:16:45
16	BY MS. MARTIN:	13:16:49
17	Q. I haven't -- sorry, let me start again	13:16:49
18	because I didn't finish my question. When you say in	13:16:51
19	paragraph 43 that you read the claims as a whole as	13:16:53
20	being directed to modified PH20 polypeptides that	13:16:57
21	satisfy the three romanettes that you've listed	13:17:01
22	there --	13:17:04

1 A. Oh I see what you mean by "romanettes". My
2 apologies.

3 Q. I'm sorry, (i), (ii) and (iii), you are
4 reading the claims as a whole as being directed to
5 modified PH20 polypeptides that have -- that meet the
6 sequence identity claim parameters, have the position
7 313 substitution, and have folded to adopt the same
8 tertiary fold, right?

9 A. I understand now. So this is not my complete
10 conclusion on the claims. In this paragraph I set
11 out my analys -- so this paragraph is the beginning
12 of me -- I talk about in the next few paragraphs
13 about my analysis, how I constructed my analysis on
14 folding. I then move in -- as at the beginning it
15 says "in ...D and ...E" and in E I separate out my
16 activity analysis. And my conclusion for what the
17 claims are read, how I have read the claims, are set
18 out in the -- entirely in the conclusion in
19 paragraph 108.

20 Q. So let's turn to paragraph 108 which starts
21 on page 71. Are you there?

22 A. Nearly. My apologies, the pages are starting

1	to come --	13:18:31
2	Q. You're fine, sorry. It's just hard to tell	13:18:32
3	when you're not in person.	13:18:32
4	A. I'm on paragraph 108 now.	13:18:37
5	Q. Okay, perfect. And so in paragraph 108 you	13:18:41
6	say:	13:18:42
7	"I believe Dr. Hecht more accurately	13:18:44
8	describes why a POSA would have read the	13:18:46
9	claims as a whole as being directed to	13:18:49
10	modified PH20 polypeptides that are	13:18:51
11	properly folded, and certain of those	13:18:53
12	being enzymatically active."	13:18:57
13	Right?	13:18:59
14	A. That's what my sentence says, yes.	13:19:00
15	Q. So certain claims are directed to PH20 --	13:19:03
16	modified PH20s that are properly folded and	13:19:06
17	enzymatically active, right?	13:19:10
18	A. No.	13:19:12
19	Q. Are you saying now all claims are directed to	13:19:19
20	PH20s that are properly folded and enzymatically	13:19:22
21	active?	13:19:25
22	A. That's the conclusion I rendered in	13:19:26

1 paragraph 109, which I said that the claims -- the 13:19:27
2 last sentence of paragraph 109 is that -- can I just 13:19:31
3 read it? That a POSA "... would have concluded that 13:19:35
4 the claims define a set of modified PH20s that 13:19:38
5 exhibit hyaluronidase activity." And that's 13:19:41
6 consistent with the sentence I've written in 13:19:44
7 paragraph 108. 13:19:46

8 Q. Okay, so let's go to -- I just want to 13:19:49
9 understand because in this declaration you say that 13:19:55
10 "... certain claims (e.g., claim 5) ...", which is 13:19:58
11 what you've written in 109 -- 13:20:05

12 A. Sorry, we're on to paragraph 109? 13:20:09

13 Q. Sorry. Sorry, yeah, let me start again. The 13:20:11
14 last sentence in paragraph 109 you say that a POSA: 13:20:14

15 "... when a POSA considers all of the 13:20:18

16 language used in certain claims (e.g., 13:20:20

17 claim 5) and does that in conjunction 13:20:23

18 with the common disclosure, she would 13:20:26

19 have concluded that the claims define a 13:20:28

20 set of modified PH20s that exhibit 13:20:31

21 hyaluronidase activity." 13:20:33

22 Right? 13:20:34

1 A. Yes, that's what this sentence says, and
2 concluded that the claims, meaning all the claims,
3 define a set of modified PH20s that exhibit
4 hyaluronidase activity.

5 Q. Okay, so you're now saying that all of the
6 claims require hyaluronidase activity and not just
7 claim 5?

8 A. I'm not now saying that, that's what the
9 declaration says.

10 Q. So in paragraph 108, when you've said that
11 the claims -- would understand the "claims as a whole
12 as being directed to modified PH20 polypeptides that
13 are properly folded, and certain of [them] being
14 enzymatically active", you meant to say that all of
15 them would be enzymatically active?

16 A. Oh, sorry, I see now. Sorry, my apologies.
17 So they're directed to modified PH20 polypeptides and
18 those that are enzymatically active. So that's what
19 it says, is that they're properly folded and are --
20 certain of -- and the ones within that population are
21 properly folded that are enzymatically active. So
22 it's the certain of the modified PH20 polypeptides

1 that are folded. There is a subset of those that are 13:21:58
2 enzymatically active. 13:22:00

3 So if we go back to -- sorry, I see the point. 13:22:02
4 I think it is the little box diagram on page 49. At 13:22:07
5 the top of page 49. 13:22:17

6 Q. Yes. 13:22:27

7 A. So we've drawn a big universe of various 13:22:28
8 sub-populations and I've shown "Natively folded 13:22:31
9 modified PH20 polypeptides", and what I'm referring 13:22:35
10 to and those that are stably enzymatically active is 13:22:40
11 the little green highlighted box, "adequate 13:22:42
12 stability", enzymatic stability. That's to where 13:22:44
13 I think the claims are directed in that box which is 13:22:48
14 a subset of the folded ones. Sorry, that's the 13:22:49
15 "certain", if that helps. 13:22:56

16 Q. Okay, so let's go back to -- actually let's 13:23:05
17 go to paragraph 100. 13:23:10

18 A. That's page 65? 13:23:26

19 Q. Yes, I think. Then, sorry, can you go to the 13:23:42
20 next page because I'm looking for the fourth sentence 13:23:45
21 in paragraph 100. So do you see the sentence that 13:23:49
22 starts: 13:23:56

1	"I agree with Dr. Hecht ..."	13:23:56
2	A. "... that this passage ... also supports ...	13:23:59
3	certain claims ... as defining modified PH20	13:24:02
4	polypeptides [as requiring] hyaluronidase activity."	13:24:02
5	Yes, I see that.	13:24:06
6	Q. Do you see that sentence?	13:24:08
7	A. I can read that, yes.	13:24:12
8	Q. All right. So you stated in your matter	13:24:13
9	46 declaration that:	13:24:16
10	"... certain claims (e.g., claim 5) ... [define]	13:24:18
11	modified PH20 polypeptides that exhibit hyaluronidase	13:24:23
12	activity."	13:24:28
13	Correct?	13:24:28
14	A. No, that's not what I'm saying. I'm saying	13:24:28
15	that --	13:24:31
16	Q. You literally said the words "certain	13:24:32
17	claims". Are you saying that you didn't use the	13:24:34
18	language "certain claims"?	13:24:36
19	MR. KUSHAN: Objection to foundation.	13:24:38
20	Objection as to form.	13:24:39
21	THE WITNESS: So what I'm saying is that that	13:24:42
22	particular passage I've highlighted helps understand	13:24:44

1 particular claim 5, for example claim 5, as defining
2 them to have hyaluronidase activity. I don't, in my
3 opinion, that having read the common disclosure in
4 its entirety, as I conclude in paragraph 109 that the
5 claims are -- all the claims are directed to the
6 active form of the protein.

7 There are -- different paragraphs dwell on
8 different points but it doesn't -- I've given you
9 what I conclude to be the analysis.

10 BY MS. MARTIN:

11 Q. So when you said in your declaration "that
12 this passage ... supports reading certain claims
13 (e.g., claim 5) as defining modified PH20
14 polypeptides that exhibit hyaluronidase activity",
15 what you meant to say was that it supports reading
16 all of the claims as defining modified PH20
17 polypeptides that exhibit hyaluronidase activity?

18 A. No. What I meant was that you read this, and
19 particularly Dr. Hecht cited this, but I have
20 previously stated that the modified PH20 polypeptide
21 as I have read the claims requires activity for a
22 whole host of reasons that I set out in

1 paragraph 108, and that this phrasing here helps you 13:26:12
2 understand that reading. It's part of the common 13:26:16
3 disclosure. It's part of what forms my opinions for 13:26:18
4 the claims. But that phrase in isolation doesn't 13:26:20
5 help -- doesn't -- isn't what I rest on for the 13:26:24
6 entire patent. 13:26:27

7 Q. Okay. Can you turn to page 69. 13:26:31

8 A. Yes, I'm on page 69. 13:26:49

9 Q. I think you had said before -- actually -- 13:26:52
10 yeah, okay, perfect. You had said before that 13:26:55
11 subsection -- okay -- that subsection E addresses the 13:26:59
12 activity; is that right? 13:27:07

13 A. That's correct, that this series of 13:27:08
14 paragraphs addresses my activity analysis. 13:27:11

15 Q. And you say the claims -- in the header for 13:27:14
16 subsection E is that "The Claims Include 13:27:18
17 Enzymatically Active Modified PH20 Polypeptides", 13:27:21
18 right? 13:27:25

19 A. Yes, that's correct, that's what the header 13:27:25
20 says. 13:27:28

21 Q. So the claims include enzymatically active 13:27:29
22 modified PH20 polypeptides but they are not limited 13:27:32

1 to enzymatically active modified PH20 polypeptides,

13:27:36

2 right?

13:27:42

3 MR. KUSHAN: Objection to foundation.

13:27:42

4 THE WITNESS: That isn't my conclusion and my

13:27:44

5 conclusion that I spell out when I say the

13:27:45

6 "conclusion" is, that the claims define a set of

13:27:47

7 modified PH20s that exhibit hyaluronidase activity,

13:27:50

8 and I give my reasons for reaching that conclusion at

13:27:54

9 the end.

13:27:57

10 BY MS. MARTIN:

13:28:01

11 Q. Sorry, what paragraph are you reading from

13:28:01

12 that says that the claims require hyaluronidase

13:28:03

13 activity?

13:28:06

14 A. As I read the claims, that is paragraph 109

13:28:06

15 where I say "and ... she would have concluded", so

13:28:12

16 that is a conclusion of my analysis in paragraph 109.

13:28:15

17 So the paragraphs are the underlying ideas and

13:28:21

18 analysis that go to reach my conclusion, and I spell

13:28:24

19 out my conclusion in 109.

13:28:27

20 Q. So based on the language that was used in

13:28:33

21 claim 5 a POSA would have concluded that all of the

13:28:35

22 claims define a set of modified PH20 polypeptides

13:28:40

1 that exhibit hyaluronidase activity? 13:28:44

2 A. That's not what I said. So in 109 I say that 13:28:46
3 "the language ... and ... in conjunction with the 13:28:51
4 common disclosure", you have to read the common 13:28:54
5 disclosure, you would have concluded or at least my 13:28:57
6 opinion is the POSA would have concluded that the 13:29:01
7 claims are directed to modified PH20s that are 13:29:03
8 enzymatic -- that exhibit hyaluronidase activity. 13:29:07

9 Q. But you used the language -- you used the 13:29:11
10 phrase "certain claims" in this paragraph, correct? 13:29:14

11 A. Yeah, that's correct, that is there but 13:29:18
12 I also state my conclusion for "the claims". I don't 13:29:21
13 say this claim or that claim, I say "the claims 13:29:24
14 define a"-- are directed to "a set of modified PH20s 13:29:27
15 that exhibit hyaluronidase activity". That is the 13:29:34
16 conclusion of my opinion or on how I have read the 13:29:36
17 claim scope. 13:29:41

18 Q. So why did you refer to "language used in 13:29:42
19 certain claims" in this sentence? 13:29:45

20 A. Because I read -- my understanding was I had 13:29:47
21 to read the patent that I was asked to and I wrote my 13:29:51
22 declaration on that. I drew attention to claim 5 as 13:29:55

1 particularly interesting but I didn't use it to 13:29:57
2 inform how I read claim 1. How I read the other 13:30:02
3 claims was to properly read the common disclosure and 13:30:07
4 test that claim independently. 13:30:10

5 Q. So then why did you call out claim 5 in this 13:30:14
6 sentence? 13:30:17

7 A. I thought it was an interesting claim to 13:30:17
8 call. I can't remember more than that, that 13:30:19
9 I remember claim 5 specifically calls out specific 13:30:21
10 mutations that are all active, and that position, 13:30:24
11 313, is one of the ones that I think Dr. Petsko 13:30:28
12 flagged as particularly tolerant, and in that claim 5 13:30:33
13 these call out the substitutions that are active. So 13:30:37
14 I thought it was worth noting but it isn't -- my 13:30:41
15 conclusion is that the claims define a set of 13:30:44
16 modified PH20s that exhibit hyaluronidase activity. 13:30:46

17 Q. Okay. Can you -- actually can you turn to 13:31:11
18 paragraph 104 in this declaration and then just keep 13:31:13
19 it handy. (Pause). And then at the same time pull 13:31:16
20 up your matter 4 declaration on the '298 patent? 13:31:28

21 A. Okay. 13:31:33

22 Q. It's Exhibit 1 for the tech. 13:31:53

1	A. Can I just check it is -- this is	13:31:56
2	PGR2025-00004, US Patent '298, my declaration, yes?	13:31:56
3	Q. Yes.	13:32:03
4	A. Yes, I've got it. Thank you.	13:32:05
5	Q. Then can you turn to paragraph 104?	13:32:06
6	A. I don't know if you can see, I'm in --	13:32:08
7	drowning in a sea of paper. I'll just move some	13:32:11
8	things is okay?	13:32:13
9	Q. I can imagine.	13:32:16
10	A. I've got paragraph 104 in my PGR2025-00004.	13:32:44
11	Q. Perfect. Okay. So do you have two	13:32:53
12	declarations side-by-side with two paragraph 104s?	13:32:55
13	A. Yes, I've got four bundles of papers but the	13:32:59
14	104 is visible to me in both, although I have to turn	13:33:03
15	the page in the PGR2025-00004 because paragraph 104	13:33:06
16	goes over to 67 and 68. So if you hear me turn the	13:33:14
17	page, it's just because the paragraph splits across	13:33:20
18	the two.	13:33:22
19	Q. Okay, yeah, that's fine. I just want to make	13:33:23
20	sure that we're -- you've got them both. All right.	13:33:24
21	So in matter 4, in paragraph 104, you say in the	13:33:28
22	third sentence:	13:33:34

1	"PH20 is expressly defined in the common	13:33:35
2	disclosure to have a form [that the]	13:33:38
3	POSA would understand ..."	13:33:43
4	Sorry.	13:33:54
5	A. Yeah, I've got the sentence.	13:33:54
6	"PH20 is expressly defined in the common	13:33:56
7	disclosure ... would understand is	13:33:58
8	folded and is enzymatically active."	13:34:02
9	Q. Yes, thank you. So that's what you say in	13:34:05
10	your matter 4 declaration, you say:	13:34:06
11	"... folded and is enzymatically active".	13:34:07
12	But in your matter 46 declaration you say that:	13:34:09
13	"PH20 is expressly defined ... to have a	13:34:17
14	form a POSA would understand is folded."	13:34:26
15	And you don't say -- you don't include the	13:34:29
16	language "enzymatically active"; correct?	13:34:31
17	A. That's correct, in the 0046 that, the words	13:34:34
18	after "is folded" aren't -- "and is enzymatically	13:34:39
19	active" are not added here, that's correct.	13:34:44
20	Q. So why did you not include the phrase	13:34:48
21	"enzymatically active" in the matter 46 declaration?	13:34:50
22	A. Because, as I said, I split my analysis	13:34:54

1 because each declaration I have to consider the test 13:34:57
2 separately, the case, and formulate my opinions for 13:35:02
3 the patent in front of me. So I split my analysis 13:35:05
4 here. So I focus mainly on the folding for this 13:35:08
5 patent in 46, and then I dealt with the enzymatic 13:35:11
6 activity in paragraphs 105 to 109. And as I've said, 13:35:14
7 at the end of paragraph 109 I give you my conclusions 13:35:20
8 to how the claims are read, which is they're 13:35:24
9 enzymatically active proteins. 13:35:27

10 Q. So you agree that PH20 has the same 13:35:29
11 definition in both the '298 patent and the '692 13:35:32
12 patent, correct, it's the same definition? 13:35:35

13 A. Yes, I do. 13:35:38

14 Q. All right. Yet in the matter 46 declaration 13:35:40
15 for the '692 patent you said that "PH20 is expressly 13:35:47
16 defined ... to have a form a POSA would understand is 13:35:51
17 folded". 13:35:55

18 And in the matter 4 declaration for the '298 13:35:57
19 patent you said "PH20 is expressly defined ... to 13:36:00
20 have a form a POSA would understand is folded and is 13:36:07
21 enzymatically active." 13:36:12

22 Correct? 13:36:13

1 A. That's correct, in those paragraphs I use 13:36:14
2 different words because I was dealing with different 13:36:16
3 patents, and I constructed my report differently 13:36:18
4 because each report I understand has to be 13:36:22
5 independently stand on its own. So my -- the way 13:36:24
6 I conducted my analysis was different here and 13:36:29
7 I wrote my report differently but my conclusion which 13:36:31
8 is given in 109 integrates across that and gives you 13:36:34
9 my analysis. 13:36:38

10 Q. So you said that you used different language 13:36:41
11 because there are different patents but it's the 13:36:43
12 same -- the patents have the same common disclosure 13:36:44
13 and they have the same definition for PH20, right? 13:36:48

14 A. That's correct, I've said that the PH20 is 13:36:51
15 the same, but I was talking about my analysis of 13:36:53
16 claim construction here. And so I analyzed my claim 13:36:56
17 construction differently here but I reach the same 13:37:03
18 conclusion and it's because the claims are 13:37:06
19 differently spelt out here, I thought -- my 13:37:07
20 understanding is I have to conduct an independent 13:37:10
21 analysis for each patent and that's what I did. 13:37:12

22 Q. So is it your testimony that PH20 is defined 13:37:15

1 in the specification to require folding and activity? 13:37:18

2 A. So PH20 is defined in the common disclosure 13:37:22
3 as in neutral-active form found in the surface of the 13:37:27
4 cell which is both folded and enzymatically active. 13:37:30

5 Q. So in your matter 46 declaration when you 13:37:37
6 just said that it's defined to include forms that are 13:37:39
7 active -- I'm sorry, forms that are folded -- 13:37:44

8 A. Yeah, that's part of it because, as I said, 13:37:51
9 I separated out my analysis of folding up to 13:37:53
10 paragraph 104 and then from heading E, I then moved 13:37:56
11 on to my analysis before rendering my final opinion 13:38:00
12 as to how I read claim construction. So it's just 13:38:04
13 that I split my analysis in folding and activity 13:38:07
14 differently in this report because I considered a 13:38:11
15 different claim language than in the '298 I think it 13:38:15
16 is -- '298. So, that is why there's a difference in 13:38:18
17 words. But my conclusion for 46 is that the claims 13:38:24
18 are directed to enzymatically active modified PH20 13:38:29
19 polypeptides. 13:38:36

20 Q. Okay. Can you turn to paragraph 43 in the 13:38:44
21 '298 declaration? 13:38:51

22 A. That's matter 4, is that correct? 13:38:53

1	Q. Yes.	13:38:54
2	(Reporter clarification)	13:39:13
3	A. Paragraph 43. Is that correct, Ms Martin?	13:39:14
4	Q. Yes. Yes, thank you.	13:39:15
5	A. That's page 19 and it splits over on to	13:39:15
6	page 20.	13:39:16
7	Q. Yes. Perfect. Then if you could turn to	13:39:20
8	paragraph 43 in the matter 46 declaration as well?	13:39:22
9	A. Yes, I'm on those two.	13:39:58
10	Q. Perfect. Okay, so in the matter 4	13:40:00
11	declaration, in paragraph 43 you say that you	13:40:02
12	"... read the claims as a whole as being directed to	13:40:06
13	modify PH20 polypeptides that ..." meet four	13:40:10
14	requirements, right?	13:40:15
15	A. That's correct.	13:40:16
16	Q. And the fourth requirement is that they "are	13:40:18
17	enzymatically active", correct?	13:40:20
18	A. That's what the paragraph says in matter 4,	13:40:23
19	yes.	13:40:25
20	Q. Okay. And then in matter 46, in	13:40:27
21	paragraph 43, as we discussed, you say that the	13:40:31
22	claims -- you "read the claims as a whole as being	13:40:35

1 directed to modified PH20 polypeptides that" satisfy 13:40:38

2 three criteria, correct? 13:40:44

3 MR. KUSHAN: Objection to foundation. 13:40:46

4 THE WITNESS: So again I'm going to come back 13:40:48

5 and say at the start I set out where I discuss my 13:40:50

6 analysis in this analysis for this patent which is 13:40:54

7 matter 46. I separated out the folding analysis from 13:40:57

8 the activity analysis. I did so because the claim 13:41:01

9 language was different. I had to consider it 13:41:05

10 independently. And my conclusion as to how I've read 13:41:07

11 the claim scope is given in paragraph 109. But the 13:41:10

12 words are different between those two paragraphs 13:41:15

13 because I approached the reading of this patent 13:41:17

14 independently from the matter 4. 13:41:20

15 BY MS. MARTIN: 13:41:26

16 Q. In any event, in paragraph 43 in the matter 13:41:23

17 46 declaration, you say that the claims as a whole 13:41:33

18 are directed to modified PH20 polypeptides that 13:41:38

19 satisfy three of your requirements, correct? 13:41:42

20 A. The sentence in this paragraph which is 13:41:44

21 beginning my analysis of folding, states that how 13:41:47

22 I have read the claims and is given in the conclusion 13:41:56

1 of the section in paragraph 109. So that is correct, 13:41:58
2 in this sentence it talks about this because 13:42:03
3 I'm gonna focus on the folding analysis here, and 13:42:05
4 then I separate out my activity analysis in this 13:42:10
5 matter and I give my conclusion at the end of 13:42:13
6 paragraph 109. 13:42:15

7 Q. But in paragraph 43 in matter 46, you say: 13:42:18

8 "As I explain in [subsections] ...D and 13:42:23
9 ...E below ..." 13:42:26

10 So, as you explain in your folding and 13:42:27
11 activity sections, right, that's how you start this 13:42:30
12 paragraph? And then you still conclude, in 13:42:35
13 paragraph 43, that you read the claims as a whole as 13:42:37
14 being directed to modified PH20 polypeptides that 13:42:41
15 satisfy three criteria; correct? 13:42:45

16 A. No, I didn't say conclude here. The 13:42:47
17 conclusion is given in the end, in paragraph 108 13:42:49
18 (sic), once I have completed my analysis. But this 13:42:52
19 section deals with the folding and the latter section 13:42:56
20 deals with activity. And my conclusion is given at 13:43:01
21 the end of the section 108 -- 109, sorry. So this is 13:43:05
22 not the conclusion, this is the prefix to beginning 13:43:10

1	to think about folding.	13:43:12
2	Q. Okay. Can you turn to paragraph 108 then in	13:43:27
3	both the matter 4 and the matter 46 declarations.	13:43:43
4	A. In the 46 that's in page 71 and goes over on	13:44:04
5	to page 73.	13:44:07
6	Q. Yes.	13:44:20
7	A. I'm just turning there in matter 4. That	13:44:21
8	begins on page 70 and ends on page 73.	13:44:23
9	Q. So do you see the first sentence in your	13:44:46
10	matter 4 declaration?	13:44:48
11	A. Yes.	13:44:51
12	Q. You say:	13:44:52
13	"I believe Dr. Hecht more accurately	13:44:53
14	describes why a POSA would have read the	13:44:55
15	claims as a whole as being directed to	13:44:57
16	modified PH20 polypeptides that are	13:45:00
17	enzymatically active."	13:45:03
18	Correct?	13:45:05
19	A. Yes, I can see that's what I've said in	13:45:05
20	declaration 4.	13:45:08
21	Q. And then in the matter 46 declaration you	13:45:10
22	say:	13:45:14

1 "I believe Dr. Hecht more accurately 13:45:16
2 describes why a POSA would have read the 13:45:18
3 claims as a whole as being directed to 13:45:20
4 modified PH20 polypeptides that are 13:45:23
5 properly folded, and certain of those 13:45:27
6 being enzymatically active." 13:45:28
7 Right? 13:45:30
8 A. That's right. 13:45:31
9 Q. So in the matter 4 declaration, you say that 13:45:31
10 the claims as a whole are directed to modified PH20 13:45:41
11 polypeptides that are enzymatically active. But in 13:45:43
12 matter 46 declaration you say a POSA would have read 13:45:51
13 the claims as a whole as being directed to modified 13:45:53
14 PH20 polypeptides that are properly folded, and 13:45:56
15 certain of those are enzymatically active. Right? 13:45:59
16 A. So I have said how I -- what the -- how 13:46:03
17 I meant the sentence to read. How it reads to me is 13:46:07
18 that in the matter 46 we're going back to the box and 13:46:10
19 I'm directing you to the specific top left-hand box, 13:46:15
20 that is the green box colored, active proteins that 13:46:19
21 are -- so the properly folded is a bigger universe. 13:46:23
22 And then -- but the claims here are directed to the 13:46:28

1 enzymatically active portion of that universe in that 13:46:31
2 corner, in this paragraph 108, that's why I used my 13:46:35
3 analysis differently because I consider different 13:46:40
4 claim language, separated out folding from the 13:46:43
5 activity analysis. 13:46:46

6 Q. I'm still trying to understand. Are you 13:46:49
7 saying that -- so you said that certain of those are 13:46:51
8 enzymatically active, meaning that the claims as 13:46:55
9 a whole are directed to properly folded PH20 13:46:57
10 polypeptides of which certain of them are 13:47:02
11 enzymatically active, right? 13:47:04

12 A. No, that's not what I meant. So what 13:47:06
13 I'm saying is that because I separated my analysis in 13:47:10
14 matter 46 to folding and activity, that I read the 13:47:15
15 claims as being directed to folded and active 13:47:19
16 proteins that just folded proteins is a bigger -- has 13:47:22
17 sub-categories within it but I -- so that's what 13:47:28
18 I dealt with in the first sections. And then when 13:47:32
19 I deal with my analysis around activity I am focused 13:47:35
20 down and the claims are directed to enzymatically 13:47:39
21 active which are also folded. 13:47:43

22 So to have activity you must be folded, but not 13:47:45

1 all folded proteins have enzymatic activity. 13:47:48

2 So what I'm doing is saying the claims are 13:47:51

3 directed to folding and within that subset of folding 13:47:53

4 only those that are enzymatically active. 13:47:57

5 Q. But that's not what you say in paragraph 108, 13:47:59

6 you say "certain of those being enzymatically 13:48:02

7 active"? 13:48:05

8 A. Yes, it's directed to certain of those that 13:48:05

9 are enzymatically active. That's how I read my 13:48:08

10 sentence. It's directed to those that are modified 13:48:14

11 and folded as well as having -- and directed to those 13:48:17

12 that are enzymatically active. 13:48:21

13 Q. So you're reading out the "certain of those"? 13:48:24

14 A. No, "certain of those" -- so as I tried to 13:48:26

15 explain what the language is meant to convey, is if 13:48:30

16 we go back to the box, page 49, that I've boxed 13:48:33

17 "Natively folded ... PH20 polypeptides" and within 13:48:47

18 that there are different types of them, and it's the 13:48:51

19 certain of those that are enzymatically active, 13:48:53

20 properly folded and stable that I believe the claims 13:48:55

21 are directed to. And because -- and that's -- so 13:48:58

22 that's what that sentence says: the certain of those 13:49:01

1 boxes that are folded, only those that are 13:49:05

2 enzymatically active is how I have construed the 13:49:07

3 claims. 13:49:10

4 Q. So if that's how you're construing the claims 13:49:16

5 here why didn't you just use the same language that 13:49:18

6 you used in the matter 4 declaration? 13:49:21

7 A. My understanding is that I have to approach 13:49:23

8 each patent independently. The claim language was 13:49:26

9 different. I read it differently and did my analysis 13:49:29

10 differently. I reached a conclusion that I rendered 13:49:31

11 in paragraph 109, which was that my conclusion is the 13:49:34

12 claims are directed to enzymatically active 13:49:39

13 hyaluronidase activity. 13:49:43

14 Q. Can you turn to paragraph 110 in the matter 13:50:37

15 46 declaration. 13:50:43

16 A. Yes. 13:50:59

17 Q. In the second sentence you say: 13:51:00

18 "I understand the panel conducting this 13:51:01

19 proceeding could conclude that the 13:51:05

20 claims are not ...". 13:51:07

21 Defined to modified PH -- or, I'm sorry: 13:51:07

22 "... that the claims are not limited to 13:51:10

1	modified PH20 polypeptides that have	13:51:12
2	stably folded."	13:51:14
3	Correct?	13:51:16
4	A. Yes, that's what I said. The panel could	13:51:17
5	conclude that. I'm not a lawyer.	13:51:19
6	Q. And you didn't say anything about enzymatic	13:51:22
7	activity in that sentence, did you?	13:51:24
8	A. That sentence doesn't have enzymatic activity	13:51:27
9	in it. And it's not my conclusion, it just meant you	13:51:30
10	know that I obviously have to be respectful of what	13:51:32
11	the board can decide.	13:51:35
12	Q. Is it possible for a PH20 to have adopted the	13:51:40
13	stable -- to have stably folded and not be	13:51:44
14	enzymatically active?	13:51:48
15	A. As a scientific point there are variants of	13:51:52
16	PH20 known in the literature that are stably folded	13:51:58
17	but have no enzymatic activity. In fact that's	13:52:02
18	known.	13:52:06
19	MS. MARTIN: We've been going for over	13:52:10
20	an hour so can we take a quick break?	13:52:12
21	MR. KUSHAN: Sure.	13:52:16
22	VIDEOGRAPHER: We are going off the record.	13:52:17

1	The time is 1:52.	13:52:18
2	(A short break)	13:52:29
3	VIDEOGRAPHER: We are back on the record.	14:06:44
4	The time is 2:06	14:06:45
5	BY MS. MARTIN:	14:06:50
6	Q. Welcome back, Dr. Naismith.	14:06:50
7	A. Hello.	14:06:52
8	Q. Did you discuss the substance of your	14:06:54
9	deposition with counsel during the break?	14:06:56
10	A. I did not.	14:06:58
11	Q. All right, so you have the common disclosure	14:06:59
12	in front of you, right?	14:07:03
13	A. It's in a folder, yes.	14:07:04
14	Q. Perfect. And so we've been talking about	14:07:07
15	your declaration in matter 46 and that covers the	14:07:09
16	'692 patent, correct?	14:07:15
17	A. Yes, I mean I believe so but I obviously want	14:07:18
18	to just turn to my front piece to check. Yes, '692,	14:07:20
19	that's correct.	14:07:25
20	Q. And the position at issue in that declaration	14:07:26
21	is position 313, correct?	14:07:28
22	A. The position that's called out in the claims,	14:07:33

1	claim 1, yes, is 313, that's correct.	14:07:35
2	Q. Okay. And actually do you have the '692	14:07:38
3	patent somewhere?	14:07:42
4	A. I have it here.	14:07:52
5	Q. Can you turn to the claims in the '692	14:07:54
6	patent? It should be on page 185. It's the	14:07:55
7	second-to-last page.	14:07:59
8	A. To make it easier, do you mind if I just	14:08:00
9	remove matter 4 from in front of me and put it to the	14:08:02
10	side.	14:08:06
11	Q. Mm-hmm, that's fine.	14:08:08
12	A. Okay, I'm on the '692 patent.	14:08:20
13	Q. Okay, and you've got the claim 1?	14:08:22
14	A. Let me find the claims, sorry.	14:08:25
15	Q. Okay. The second-to-last page.	14:08:28
16	A. Okay. There's bulldog clips. (Pause).	14:08:31
17	Yes.	14:08:35
18	VC TECHNICIAN: Would you like me to share	14:08:46
19	this on screen, Ms Martin?	14:08:47
20	BY MS. MARTIN:	14:08:48
21	Q. Yeah, if you want to, that's fine. Thank	14:08:48
22	you. Okay, are you there, Dr. Naismith?	14:08:49

1	A. Yes, I am, I'm on the claims section.	14:08:52
2	Q. Perfect. And so just confirming the '692	14:08:54
3	patent, the position at issue is position 313?	14:08:56
4	A. I'm confirming, yes, that in claim 1 it says	14:09:00
5	the modified position and it spells out 313 with	14:09:03
6	reference to SEQ ID No:3.	14:09:07
7	Q. Okay, thank you. And just to confirm we're	14:09:12
8	all on the same page here. That you interpret claim	14:09:13
9	1 of the '692 patent which requires modified PH20	14:09:16
10	polypeptides with a modification at position 313, you	14:09:23
11	interpret claim 1 to be limited to properly folded	14:09:26
12	and enzymatically active proteins, correct?	14:09:31
13	A. That's correct, that's how I read the claim.	14:09:36
14	Q. All right. Now can you turn in the common	14:09:42
15	disclosure, Exhibit 1026, to page 135.	14:09:48
16	(Previously marked Exhibit 1026 identified.)	14:09:53
17	A. I'm going to put aside the patent 692, if	14:09:56
18	that's okay?	14:09:59
19	Q. Yes.	14:10:01
20	A. What page of the common disclosure, please,	14:10:08
21	sorry?	14:10:11
22	Q. Page 135.	14:10:11

1 A. What numbers do you want me to use, the
2 bottom right, which says Petitioner Merck extract
3 page numbers, or the column page numbers in the
4 center? There's two numbers on each page so I just
5 want to be sure I get the right one for you.

6 Q. Sorry, I had it and then -- one second here.
7 (Pause). Okay, on the Petitioner Merck Ex. 1026,
8 page 148.

9 A. Okay, I'll get there.

10 Q. And to orient ourselves, if you look at
11 Merck's page 145, you see that this is Table 5,
12 inactive mutants?

13 A. Yes, I can see that's what it says. It's
14 Table 5, yeah.

15 Q. Okay. Now if you turn back to Merck's
16 page 148. Do you see maybe about a little bit of the
17 ways down the page, position 313, the right-hand
18 column?

19 A. Yes, I do.

20 Q. And there is one amino acid listed in that
21 column for inactive mutants, and that one variant is
22 cysteine; correct?

1 A. So the patent has classified that variant 313
2 as inactive in its classification.

3 Q. So the patent teaches that modifying position
4 313 to a cysteine results in an inactive PH20,
5 correct?

6 A. I disagree, I don't think that's what the
7 patent teaches. The patent teaches that it is at 313
8 less than 20% activity in the assay they deployed.

9 Q. I understand. So it's -- so position 313
10 mutation to cysteine is classified as an inactive
11 mutant but the classification was based on less than
12 20% activity; is that right?

13 A. That's correct, that's how the patent
14 classifies inactive mutants.

15 Q. So under your construction of claim 1 of the
16 '692 patent would the mutation to cysteine at
17 position 313 that is taught in the patent, would that
18 variant satisfy claim 1?

19 A. It might do because the reasons for why it
20 was under 20% activity were not disclosed or
21 investigated by the -- in the disclosure. So if the
22 mutant was 19% active it would have been classified

1 as inactive, but I would have classified 19% as

14:13:54

2 an active form of the protein.

14:13:59

3 Q. I think you said that the reasons why it was
4 under 20% activity were not disclosed. What did you
5 mean by that?

14:14:06

14:14:12

14:14:17

6 A. What I meant was that in the assay that is in
7 the patent, they imposed their own threshold, so I've
8 got no numbers to know what was actually measured.

14:14:19

14:14:23

14:14:27

9 Was the protein secreted, folded, made? Was it 19%

14:14:29

10 active? Any one of those, and other factors, could

14:14:34

11 have led to a protein being classified as inactive.

14:14:37

12 And what I mean here is that the M313 cysteine which

14:14:40

13 was 19% active would have still ended up in this

14:14:46

14 table as classified inactive but if it was 19% then

14:14:49

15 I would have included that as within the scope

14:14:54

16 because that is an active form of the protein.

14:14:57

17 Q. So you don't know one way or the other

14:15:06

18 whether the variant with the cysteine at position 313

14:15:08

19 falls within the scope of claim 1 of the '692 patent?

14:15:13

20 A. I believe that the patent doesn't give me the

14:15:17

21 information necessary to make that call for the M313,

14:15:19

22 that's correct.

14:15:23

1 Q. You said M313, but I just want to make sure 14:15:25
2 that we're clear that it's M313 to cysteine, correct? 14:15:29

3 A. Yes, sorry, to be -- that's just -- my 14:15:35
4 apologies. M313C, the patent doesn't give me the 14:15:36
5 information or disclose the information that would 14:15:42
6 allow me to tell you whether it is active or not, and 14:15:45
7 since 19% activity would be classified as inactive by 14:15:48
8 the patent, 19% activity would be in my terms active 14:15:51
9 and any POSA would see it so that would be within the 14:15:55
10 scope. 14:15:59

11 Q. And I believe we discussed in your last 14:16:04
12 deposition that your threshold for activity was 14:16:06
13 around -- was 5%, am I remembering that right? 14:16:09

14 A. So we discussed that and we talked about a 14:16:13
15 POSA tends to think around 5. But Dr. Petsko said, 14:16:20
16 "Sort of, well, maybe 5 up to 10". But Dr. Simpson's 14:16:24
17 paper, design paper, uses 5. And I said that most 14:16:30
18 POSAs would use 5, but my analysis wouldn't change if 14:16:34
19 we said 10 here because it's, you know, anything 14:16:37
20 below 20 would be classified as inactive. So I gave 14:16:41
21 you 19% which I think all of us, Dr. Simpson, 14:16:45
22 Dr. Petsko, myself, any POSA would agree is an active 14:16:52

1	protein.	14:16:55
2	Q. Is an active protein.	14:16:56
3	A. An ac -- is active. Sorry, "an". My	14:16:59
4	apologies.	14:17:02
5	Q. That's fine. No, it's just for the	14:17:03
6	transcript. I'm having the same difficulty.	14:17:04
7	A. Okay, sorry. M313C if it had 19% activity	14:17:09
8	would be, by my definition and I believe any POSAs,	14:17:13
9	an active protein, therefore would be in the scope.	14:17:16
10	Q. Thank you.	14:17:20
11	A. Is that hopefully clear?	14:17:21
12	Q. Yes. Thank you. And before the break you	14:17:23
13	said that there are variants of PH20 known in the	14:17:28
14	literature that are stably folded but have no	14:17:34
15	enzymatic activity, correct?	14:17:37
16	A. Yes, I said that.	14:17:38
17	Q. Was that known before the priority date?	14:17:40
18	A. Let me -- I want to check the Simpson paper,	14:17:46
19	if it had been investigated. I think it was known	14:17:49
20	because people had mutated the key glutamate residue	14:17:54
21	that was identified as a catalytic mechanism in	14:18:00
22	ArMing. They had made that mutation so it was known	14:18:04

1 that that could be expressed and purified but had no 14:18:07
2 activity. 14:18:10

3 Q. How do you know that it was stably folded if 14:18:21
4 it had no activity? 14:18:24

5 A. It was able to be isolated, it was able to be 14:18:26
6 secreted and analyzed so I assumed therefore it would 14:18:29
7 be folded. And you can do other tests -- I'd have to 14:18:32
8 familiarize myself with the ArMing paper to check all 14:18:38
9 the things that were done in it. 14:18:42

10 Q. I'm just trying to understand as a general 14:18:43
11 matter. 14:18:45

12 A. Okay, as a general matter then if the protein 14:18:46
13 can be purified or can behave on a size exclusion 14:18:50
14 column then you would assume that it was properly 14:18:56
15 folded. If you had made a single mutation at the 14:18:59
16 catalytic site, for publications in science, 14:19:02
17 sometimes you will see people do circular dichroism 14:19:07
18 measurements. In other papers people will accept a 14:19:11
19 simple what's called blue native or blue native 14:19:14
20 SDS-page, or you can do gel filtration 14:19:23
21 chromatography, and so those may be acceptable. 14:19:29

22 For very precise enzymatic studies, sometimes 14:19:32

1 people like to determine a crystal structure of the 14:19:35
2 mutant. 14:19:38

3 So you will see a variety of things used in the 14:19:39
4 literature but as a minimum threshold that the 14:19:42
5 protein has to be isolated because unfolded proteins 14:19:45
6 tend to aggregate and don't behave normally on 14:19:49
7 purification. 14:19:54

8 Q. Would you say that a crystal structure is 14:20:06
9 necessary to know whether or not a protein has been 14:20:08
10 stably folded? 14:20:13

11 A. No, I didn't say that. I said that for 14:20:14
12 people who are very interested in particular 14:20:20
13 subtleties of enzyme mechanism, they might go on and 14:20:24
14 determine the crystal structure of a properly folded 14:20:27
15 inactive protein, and so you sometimes see that in 14:20:31
16 publications, but it's not a threshold test. 14:20:32

17 Q. Do you know one way or the other whether 14:20:37
18 changing the methionine at position 313 to a 14:20:40
19 cysteine, would you expect that to result in 14:20:44
20 an unfolded protein? 14:20:49

21 A. So we know that that position tolerates quite 14:20:56
22 a few changes and there are a number of active 14:20:58

1	mutants described for that protein, and Dr. Petsko	14:21:01
2	I think highlights it in his box as one of the -- not	14:21:07
3	the most tolerated but one of the more tolerated	14:21:10
4	positions for change. If I made that mutant then	14:21:14
5	I think maybe -- I don't have any reason to suspect	14:21:17
6	it would be unfolded but I don't know. I would be	14:21:20
7	surprised, but surprises happen in science, so.	14:21:27
8	Q. Would you expect that mutant to be active	14:21:32
9	under your threshold?	14:21:36
10	MR. KUSHAN: Objection to the foundation. Go	14:21:37
11	ahead.	14:21:39
12	THE WITNESS: So I didn't consider whether	14:21:41
13	the mutant made here would be active above 5%. What	14:21:44
14	I said was that the patent, it could well be in the	14:21:48
15	patent declaration, the patent's common disclosure,	14:21:53
16	that it could be above 5%. Would I suspect it?	14:21:58
17	That's a good question, you know. Maybe -- I hadn't	14:22:02
18	thought a lot about whether -- I'd have to think	14:22:04
19	about that. Cysteine can be tricky sometimes. You	14:22:09
20	might have to adjust the buffers because cysteine can	14:22:12
21	stick to itself or tubes. You know, it's quite	14:22:16
22	inactive so sometimes you can just slip in a bit of	14:22:20

1 reductant to keep the solution reduced. That can
2 prevent aggregation.

3 So this position does tolerate quite a few
4 changes so I can't see an obvious reason why it would
5 inactivate or unfold but these things sometimes are
6 unexpected, as I pointed out previously.

7 Q. And if it were the case that the cysteine --
8 the M313C variant had less than 5% activity then you
9 would agree that it would not satisfy claim 1 under
10 your construction?

11 MR. KUSHAN: Objection to foundation.

12 THE WITNESS: So what I would say is if you
13 isolated M313C and in a robust well-performed assay
14 the enzyme had less than 5% activity then I would
15 agree that is an inactive protein. And since my
16 reading of the claims are they are directed to the
17 active forms of these mutants, then that -- in that
18 case, where you'd done that experiment, it would be
19 excluded, correct.

20 BY MS. MARTIN:

21 Q. Okay. And then can you turn, please, in
22 Exhibit 1026 to, I wrote down page 67 but I'm not

1	sure if that's --	14:23:49
2	A. Well I'll turn to both pages and we can find	14:23:51
3	out which one. I don't want to waste your time. So	14:23:53
4	67 is full of text and that is the patent numbering.	14:23:56
5	So at the top it says where the full length sequence	14:24:09
6	is compared. In the exhibit --	14:24:11
7	Q. Yes, it looks like the exhibit page 67.	14:24:15
8	A. Okay, perfect. So the exhibit, page 67, has	14:24:17
9	95%, 96%, 97%, 98% or 99%. Is that --	14:24:21
10	Q. Yes.	14:24:27
11	A. Yes, we're on the same page. Perfect.	14:24:28
12	Q. Perfect. Then do you see the paragraph that	14:24:30
13	says:	14:24:32
14	"As used herein, modified PH20	14:24:33
15	polypeptide ..."	14:24:37
16	A. That begins on line 5.	14:24:40
17	Q. Yes.	14:24:43
18	A. Yes, that I think is one of the paragraphs	14:24:43
19	I excerpted in my declaration.	14:24:46
20	Q. Yes, and so that paragraph you agree provides	14:24:49
21	the definition for a modified PH20 polypeptide?	14:24:52
22	A. It is -- that paragraph is one of the places	14:24:58

1 where you -- in forming my opinion for how to read
2 the claims that I read, yes, and relied on. It was
3 part of the evidence for it in forming my opinion.

4 Q. So you agreed that modified PH20 polypeptide
5 is a defined term in the common disclosure, correct?

6 A. So within the common disclosure it is
7 defined, yes.

8 Q. And the definition appears in the paragraph
9 that we are looking at, starting at line 5, on
10 page 67, correct?

11 A. So it's one of the places that you can find
12 in the patent where that is defined but, as I said,
13 it's not the -- that isolated phrase or isolated
14 sentence isn't the basis for how I read the claims
15 but here is a definition of it given.

16 Q. Okay, so what I would like you to do is to
17 read into the record whatever portion of this
18 paragraph, starting at line 5, you believe is the
19 definition for a modified PH20 polypeptide? So
20 please start reading and then stop at what you
21 believe to be the end of the definition for modified
22 PH20 polypeptide?

1	A. Of course.	14:26:17
2	MR. KUSHAN: Objection to form. Objection to	14:26:18
3	foundation.	14:26:21
4	THE WITNESS: So, I'm going to read the	14:26:22
5	paragraph, and I said that it appears elsewhere, but	14:26:23
6	I'm going to read this entire paragraph because this	14:26:26
7	was part of the things that went into my analysis.	14:26:29
8	"As used herein, 'modified PH20 polypeptide'	14:26:32
9	or 'variant PH20 polypeptide' refers to a PH20	14:26:37
10	polypeptide that contains at least one amino acid	14:26:43
11	modification, such as at least one amino acid	14:26:46
12	replacement as described herein, in its sequence of	14:26:49
13	amino acids compared to a reference unmodified PH20	14:26:52
14	polypeptide. A modified PH20 polypeptide can have up	14:26:57
15	to 150 amino acid replacements, so long as the	14:27:01
16	resulting modified PH20 polypeptide exhibits	14:27:05
17	hyaluronidase activity. Typically, a modified PH20	14:27:10
18	polypeptide contains 1 ..."	14:27:14
19	And I'm just going to abridge the numbers:	14:27:17
20	"... or 50 amino acid replacements. It is	14:27:19
21	understood that a modified PH20 polypeptide ... can	14:27:22
22	include one or more other modifications, in ... at	14:27:27

1	least one amino acid replacement as described	14:27:30
2	herein."	14:27:33
3	BY MS. MARTIN:	14:27:43
4	Q. So you read the full paragraph as the	14:27:43
5	definition of "modified PH20 polypeptide"?	14:27:44
6	MR. KUSHAN: Objection to foundation.	14:27:49
7	THE WITNESS: No, I read the full paragraph	14:27:51
8	as where the definition is set out and it is one of	14:27:52
9	the things that went into forming my opinion as to	14:27:54
10	how the claims should be read, but I pointed out that	14:27:57
11	I read the disclosure as a whole in forming my	14:28:01
12	opinion as to how the claims were read.	14:28:05
13	MS. MARTIN: All right, can we go off the	14:28:08
14	record and take a quick break?	14:28:11
15	VIDEOGRAPHER: We are going off the record.	14:28:13
16	The time is 2:28.	14:28:14
17	(A short break)	14:28:18
18	VIDEOGRAPHER: We are back on the record.	14:33:29
19	The time is 2:33.	14:33:30
20	MS. MARTIN: Perfect. I don't have any	14:33:33
21	further questions.	14:33:35
22	MR. KUSHAN: And we have no questions.	14:33:38

1	THE VIDEOGRAPHER: Okay. This concludes the	14:33:40
2	deposition. We are going off the record. The time	14:33:41
3	is 2:33 p.m.	14:33:42
4	COURT REPORTER: Before we go off the record,	14:33:43
5	can I have the orders obtained on the record?	14:33:43
6	MR. KUSHAN: If you could send a rough, that	14:33:54
7	would be great.	14:33:55
8	MS. MARTIN: Yes, please.	14:33:57
9	MR. KUSHAN: Lauren, do you need to order,	14:33:59
10	timing wise?	14:34:00
11	MS. MARTIN: Oh yeah. Can we get the	14:34:02
12	expedited or whatever -- (Off the record discussion).	14:34:02
13	If you could do the one day, that would be	14:34:42
14	great. (Off the record discussion). So if we can	14:34:42
15	get the final on Monday, that would be great. Thanks	14:35:12
16	so much everybody. Do you need anything else from	14:35:23
17	us?	14:35:24
18	MR. KUSHAN: No.	14:35:31
19	COURT REPORTER: No, thank you.	14:35:32
20	VIDEOGRAPHER: Thank you.	14:35:32
21	(Whereupon, the deposition concluded at 2:35 p.m.)	
22		

CERTIFICATE OF DEPONENT

I, JAMES NAISMITH, Ph.D., hereby certify that I have read and examined the entire transcript of my deposition and attest that it is a true and correct transcription of my deposition testimony given on Saturday, June 13, 2026, save and except for the changes and/or corrections, if any, listed on the Errata Sheet attached.

Signed _____

JAMES NAISMAITH, PH.D.

Dated this _____ day of _____, 2026.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

ERRATA SHEET

Case Name: Merck Sharp & Dohme LLC v. Halozyme, Inc.

Witness Name: James Naismith, Ph.D.

Page / Line	From	To
____ / ____	_____	_____
____ / ____	_____	_____
____ / ____	_____	_____
____ / ____	_____	_____
____ / ____	_____	_____
____ / ____	_____	_____
____ / ____	_____	_____
____ / ____	_____	_____
____ / ____	_____	_____
____ / ____	_____	_____
____ / ____	_____	_____

Subscribed and sworn to before
me this _____ day of _____, 2026.

JAMES NAISMITH, PH.D.

CERTIFICATE OF COURT REPORTER

I, CHANELLE MALLIFF, a Certified LiveNote Reporter, Accredited Court Reporter, and Qualified Realtime Reporter, hereby certify that:

JAMES NAISMITH, Ph.D., the witness whose deposition is hereinbefore set forth, was duly sworn by me before the commencement of such deposition and that such deposition was taken before me and is a true record of the testimony given by such witness.

I further certify that the adverse party, the Petitioner MERCK SHARP & DOHME LLC, was represented by counsel at the deposition.

I further certify that the deposition of JAMES NAISMITH, Ph.D., occurred at the offices of The Randolph Hotel Beaumont Street Oxford, OX1 2LN, United Kingdom on Saturday, June 13, 2026, commencing at 12:41 p.m. to 2:35 p.m.

I further certify that I am not related to any of the parties to this action by blood or marriage, I am not employed by or an attorney to any of the parties to this action, and that I am in no way interested, financially or otherwise, in the outcome of this matter.



CHANELLE MALLIFF

CLR, ACR, QRR2*

June 14, 2026

A			
a"-	across	20:14, 21:4,	adjust
41:14	43:17, 46:8	22:12, 24:18,	67:20
able	action	25:2, 27:8,	adopt
28:19, 65:5	76:23, 76:25	27:13, 30:13,	30:1, 32:7
about	active	31:7, 31:8,	adopted
7:21, 9:1,	20:8, 20:20,	32:16, 34:5,	56:12
14:5, 18:9,	21:7, 23:1,	34:21, 35:4,	adverse
19:4, 19:14,	23:6, 23:10,	35:6, 37:4,	76:12
22:4, 22:7,	24:4, 26:4,	37:12, 38:2,	after
28:19, 30:16,	26:5, 26:6,	38:14, 38:17,	16:18, 16:20,
32:12, 32:13,	26:8, 26:13,	38:21, 39:12,	17:13, 17:15,
46:15, 50:2,	26:18, 26:19,	39:14, 40:7,	17:20, 18:1,
51:1, 56:6,	27:1, 27:12,	40:13, 41:1,	18:10, 19:14,
57:14, 60:16,	27:16, 27:20,	41:8, 41:15,	44:18
63:14, 67:18,	27:21, 28:6,	42:16, 45:6,	afternoon
67:19	33:12, 33:17,	47:1, 47:13,	6:13, 6:14
above	33:21, 35:14,	49:8, 50:4,	again
14:10, 67:13,	35:15, 35:18,	50:11, 50:20,	8:9, 8:11,
67:16	35:21, 36:2,	53:5, 53:14,	16:1, 25:14,
abridge	36:10, 38:6,	53:19, 53:22,	25:17, 31:17,
71:19	39:17, 39:21,	54:1, 55:13,	34:13, 49:4
ac	40:1, 42:10,	56:7, 56:8,	aggregate
64:3	42:13, 44:8,	56:17, 61:8,	66:6
accept	44:11, 44:19,	61:12, 61:20,	aggregation
65:18	44:21, 45:9,	62:4, 63:7,	68:2
acceptable	45:21, 47:4,	63:8, 63:12,	agree
65:21	47:7, 47:18,	64:7, 64:15,	14:19, 18:17,
accredited	48:17, 51:17,	65:2, 65:4,	18:22, 22:17,
76:3	52:6, 52:11,	68:8, 68:14,	23:7, 24:7,
accurate	52:15, 52:20,	71:17	24:16, 26:1,
30:6	53:1, 53:8,	actually	28:5, 37:1,
accurately	53:11, 53:15,	36:16, 39:9,	45:10, 63:22,
33:7, 51:13,	53:21, 54:4,	42:17, 58:2,	68:9, 68:15,
52:1	54:7, 54:9,	62:8	69:20
acid	54:12, 54:19,	added	agreed
16:9, 17:1,	55:2, 55:12,	44:19	23:2, 23:3,
17:12, 19:6,	56:14, 59:12,	adding	28:16, 28:22,
19:9, 24:11,	61:22, 62:2,	28:10	70:4
24:12, 29:19,	62:10, 62:13,	additional	ahead
60:20, 71:10,	62:16, 63:6,	18:14	67:11
71:11, 71:15,	63:8, 63:22,	address	all
71:20, 72:1	64:2, 64:3,	28:7	2:18, 3:4, 6:1,
acids	64:9, 66:22,	addresses	6:18, 9:5,
24:14, 71:13	67:8, 67:13,	39:11, 39:14	11:10, 13:4,
acr	68:17	addressing	13:17, 16:14,
1:31, 76:30	active"	29:3	18:17, 20:22,
	44:16	adequate	26:21, 27:10,
	activity	36:11	28:5, 29:8,
	17:4, 19:8,		

Transcript of James Naismith, Ph.D.
Conducted on June 13, 2026

78

33:19, 34:15, 35:2, 35:5, 35:14, 37:8, 38:5, 38:16, 40:21, 42:10, 43:20, 45:14, 54:1, 57:11, 59:8, 59:14, 63:21, 65:8, 72:13 allow 63:6 already 11:16, 11:18, 11:19, 11:21 also 3:16, 5:22, 9:11, 11:3, 11:13, 12:14, 13:2, 26:4, 27:10, 37:2, 41:12, 53:21 although 43:14 amahan@sidley 2:12 amino 16:9, 17:1, 17:12, 19:6, 19:9, 24:11, 24:12, 24:14, 29:19, 60:20, 71:10, 71:11, 71:13, 71:15, 71:20, 72:1 amy 2:11, 8:21, 9:2 analys 32:11 analysis 21:19, 30:7, 30:10, 30:17, 31:5, 31:8, 32:13, 32:16, 38:9, 39:14, 40:16, 40:18, 44:22, 45:3, 46:6, 46:9,	46:15, 46:21, 47:9, 47:11, 47:13, 49:6, 49:7, 49:8, 49:21, 50:3, 50:4, 50:18, 53:3, 53:5, 53:13, 53:19, 55:9, 63:18, 71:7 analyzed 46:16, 65:6 any 7:1, 7:2, 7:20, 8:1, 9:14, 9:22, 13:11, 19:10, 24:18, 49:16, 62:10, 63:9, 63:22, 64:8, 67:5, 72:20, 74:8, 76:23, 76:24 anyone 8:16 anything 7:11, 8:1, 56:6, 63:19, 73:16 apologies 8:15, 17:22, 25:16, 32:2, 32:22, 35:16, 63:4, 64:4 appeal 1:3, 6:19 appears 17:13, 21:15, 70:8, 71:5 applied 18:8 appreciate 6:17 approach 55:7 approached 21:19, 49:13 aren't 44:18	arming 64:22, 65:8 around 53:19, 63:13, 63:15 arrangements 9:11 aside 59:17 asked 26:12, 41:21 asking 18:9 assay 61:8, 62:6, 68:13 assess 26:12 assume 65:14 assumed 65:6 attached 74:9 attending 6:1 attention 9:12, 41:22 attest 74:5 attorney 5:16, 76:24 attorney-client 9:14 aubrey 3:23 austin 2:5, 5:18, 8:21 available 6:17 avenue 2:21 aware 9:17, 9:20 B back 8:8, 14:16,	16:14, 24:5, 25:14, 36:3, 36:16, 49:4, 52:18, 54:16, 57:3, 57:6, 60:15, 72:18 bag 7:14 base 20:20, 21:7, 22:12 based 25:4, 40:20, 61:11 basis 70:14 beaumont 1:25, 5:11, 76:18 because 26:11, 31:18, 34:9, 36:20, 41:20, 43:15, 43:17, 44:22, 45:1, 46:2, 46:4, 46:11, 46:18, 47:8, 47:14, 49:8, 49:13, 50:2, 53:3, 53:13, 54:21, 61:19, 62:16, 63:19, 64:20, 66:5, 67:20, 71:6 been 56:19, 57:14, 61:22, 64:19, 66:9 before 1:3, 39:9, 39:10, 47:11, 64:12, 64:17, 73:4, 75:18, 76:8, 76:9 beginning 5:15, 19:17, 32:11, 32:14, 49:21, 50:22
--	--	--	---

begins 5:4, 13:12, 16:17, 18:1, 18:13, 19:3, 19:8, 29:11, 30:8, 51:8, 69:16 behalf 5:13, 6:5 behave 65:13, 66:6 being 6:15, 7:13, 15:17, 18:7, 24:1, 29:17, 31:13, 31:20, 32:4, 33:9, 33:12, 35:12, 35:13, 48:12, 48:22, 50:14, 51:15, 52:3, 52:6, 52:13, 53:15, 54:6, 62:11 believe 33:7, 51:13, 52:1, 54:20, 57:17, 62:20, 63:11, 64:8, 70:18, 70:21 below 15:22, 17:4, 50:9, 63:20 besides 7:12, 7:20 between 49:12 big 36:7 bigger 52:21, 53:16 bit 60:16, 67:22 blah 18:5 blood 76:23 blue 65:19	board 1:3, 6:19, 9:17, 28:2, 28:4, 28:14, 56:11 boston 2:22 both 43:14, 43:20, 45:11, 47:4, 51:3, 69:2 bottom 60:2 box 10:13, 12:15, 12:21, 36:4, 36:11, 36:13, 52:18, 52:19, 52:20, 54:16, 67:2 boxed 54:16 boxes 55:1 break 56:20, 57:2, 57:9, 64:12, 72:14, 72:17 bring 7:19 brought 8:4, 11:6 bst 1:22 buffers 67:20 bulk 28:7 bulldog 58:16 bundles 43:13 c call 42:5, 42:8, 42:13, 62:21 called 57:22, 65:19	calls 42:9 can't 9:3, 26:21, 42:8, 68:4 cap 23:13 captures 15:3 case 1:14, 5:7, 11:14, 12:2, 12:3, 19:2, 45:2, 68:7, 68:18, 75:2 catalytic 64:21, 65:16 cell 26:14, 27:2, 27:6, 47:4 center 60:4 certain 20:22, 33:11, 33:15, 34:10, 34:16, 35:13, 35:20, 35:22, 36:15, 37:3, 37:10, 37:16, 37:18, 38:12, 41:10, 41:19, 52:5, 52:15, 53:7, 53:10, 54:6, 54:8, 54:13, 54:14, 54:19, 54:22 certificate 74:1, 76:1 certified 76:2 certify 74:3, 76:4, 76:12, 76:16, 76:22 chance 13:11 chanelle 1:31, 6:4, 76:2, 76:29 change 28:10, 63:18, 67:4 changes 66:22, 68:4, 74:8 changing 66:18 check 7:17, 10:20, 17:20, 43:1, 57:18, 64:18, 65:8 chelsea 2:14 chimes@sidley 2:15 choi 2:27 choices 26:21 chromatography 65:21 circular 65:17 cited 38:19 claim 28:1, 28:5, 28:13, 28:17, 29:1, 29:3, 29:5, 29:21, 32:6, 34:10, 34:17, 35:7, 37:10, 38:1, 38:13, 40:21, 41:13, 41:17, 41:22, 42:2, 42:4, 42:5, 42:7, 42:9, 42:12, 46:16, 47:12, 47:15, 49:8, 49:11, 53:4, 55:8, 58:1, 58:13, 59:4, 59:8, 59:11, 59:13,
---	---	---

61:15, 61:18, 62:19, 68:9 claims 20:22, 21:2, 27:11, 27:15, 27:19, 28:6, 29:17, 30:15, 31:4, 31:13, 31:19, 32:4, 32:10, 32:17, 33:9, 33:15, 33:19, 34:1, 34:4, 34:10, 34:16, 34:19, 35:2, 35:6, 35:11, 36:13, 37:3, 37:10, 37:17, 37:18, 38:5, 38:12, 38:16, 38:21, 39:4, 39:15, 39:16, 39:21, 40:6, 40:12, 40:14, 40:22, 41:7, 41:10, 41:12, 41:13, 41:19, 42:3, 42:15, 45:8, 46:18, 47:17, 48:12, 48:22, 49:17, 49:22, 50:13, 51:15, 52:3, 52:10, 52:13, 52:22, 53:8, 53:15, 53:20, 54:2, 54:20, 55:3, 55:4, 55:12, 55:20, 55:22, 57:22, 58:5, 58:14, 59:1, 68:16, 70:2, 70:14, 72:10, 72:12 clari 18:16 clarification 11:7, 26:15,	48:2 clarifications 7:1 clarify 15:16 classification 61:2, 61:11 classified 61:1, 61:10, 61:22, 62:1, 62:11, 62:14, 63:7, 63:20 classifies 61:14 clear 18:16, 19:5, 26:22, 63:2, 64:11 clearly 19:2, 27:18 clips 58:16 clr 1:31, 76:30 colored 52:20 column 60:3, 60:18, 60:21, 65:14 com 2:10, 2:12, 2:15, 2:25, 2:28, 2:30, 3:11, 3:13 come 33:1, 49:4 comes 19:14 commencement 76:8 commencing 76:19 common 4:23, 8:9, 13:18, 13:20, 14:2, 14:17, 15:17, 16:21, 20:5, 21:1,	21:12, 21:15, 21:21, 22:9, 22:21, 23:8, 24:1, 24:16, 25:11, 25:18, 26:2, 34:18, 38:3, 39:2, 41:4, 42:3, 44:1, 44:6, 46:12, 47:2, 57:11, 59:14, 59:20, 67:15, 70:5, 70:6 communications 9:15 compared 24:14, 69:6, 71:13 complete 14:22, 15:1, 15:12, 30:7, 32:9 completed 50:18 computer 7:11, 7:13, 7:14, 7:15, 7:17, 7:18 concept 19:4 conclude 24:3, 31:10, 38:4, 38:9, 50:12, 50:16, 55:19, 56:5 concluded 34:3, 34:19, 35:2, 40:15, 40:21, 41:5, 41:6, 73:21 concludes 73:1 conclusion 26:22, 30:16, 32:10, 32:16, 32:18, 33:22, 40:4, 40:5, 40:6, 40:8,	40:16, 40:18, 40:19, 41:12, 41:16, 42:15, 46:7, 46:18, 47:17, 49:10, 49:22, 50:5, 50:17, 50:20, 50:22, 55:10, 55:11, 56:9 conclusions 30:14, 31:9, 45:7 conduct 46:20 conducted 46:6 conducting 55:18 confirm 59:7 confirming 59:2, 59:4 conjunction 21:1, 34:17, 41:3 consider 10:4, 10:8, 30:13, 45:1, 49:9, 53:3, 67:12 considered 20:5, 20:18, 20:22, 21:2, 21:10, 22:21, 30:9, 47:14 considers 34:15 consistent 34:6 constructed 32:13, 46:3 construction 28:17, 29:1, 29:4, 29:5, 46:16, 46:17, 47:12, 61:15, 68:10 construed 55:2
---	--	--	--

construing 55:4 contain 29:19 contains 18:4, 24:10, 71:10, 71:18 contents 10:4, 10:8 continue 13:22, 29:5 continued 3:2 convey 54:15 copies 12:18 copy 13:12 corner 53:2 correct 10:22, 11:2, 12:1, 12:22, 13:19, 14:4, 16:5, 17:5, 17:14, 20:9, 20:10, 20:14, 25:21, 26:10, 29:13, 30:4, 37:13, 39:13, 39:19, 41:10, 41:11, 44:16, 44:17, 44:19, 45:12, 45:22, 46:1, 46:14, 47:22, 48:3, 48:15, 48:17, 49:2, 49:19, 50:1, 50:15, 51:18, 56:3, 57:16, 57:19, 57:21, 58:1, 59:12, 59:13, 60:22, 61:5, 61:13, 62:22, 63:2, 64:15, 68:19, 70:5,	70:10, 74:5 corrections 74:8 could 5:14, 12:14, 48:7, 55:19, 56:4, 62:10, 65:1, 67:14, 67:16, 73:6, 73:13 counsel 3:22, 5:14, 6:22, 7:1, 9:7, 9:13, 57:9, 76:14 couple 9:10 course 6:3, 10:16, 28:1, 71:1 court 1:30, 6:4, 6:6, 7:9, 11:15, 11:19, 73:4, 73:19, 76:1, 76:3 covers 57:15 criteria 49:2, 50:15 cross-examination 7:3 crystal 66:1, 66:8, 66:14 cysteine 60:22, 61:4, 61:10, 61:16, 62:12, 62:18, 63:2, 66:19, 67:19, 67:20, 68:7 D date 4:19, 4:22, 5:9, 64:17 dated 74:18	day 73:13, 74:18, 75:19 dc 2:7, 3:8 deal 31:7, 53:19 dealing 46:2 deals 50:19, 50:20 dealt 45:5, 53:18 decide 28:14, 56:11 decisions 9:18, 10:1, 10:5, 10:9 declaration 4:12, 4:15, 10:12, 11:4, 11:9, 11:13, 12:11, 13:9, 14:1, 16:12, 17:7, 17:8, 18:10, 19:13, 27:18, 27:19, 29:15, 30:9, 34:9, 35:9, 37:9, 38:11, 41:22, 42:18, 42:20, 43:2, 44:10, 44:12, 44:21, 45:1, 45:14, 45:18, 47:5, 47:21, 48:8, 48:11, 49:17, 51:10, 51:20, 51:21, 52:9, 52:12, 55:6, 55:15, 57:15, 57:20, 67:15, 69:19 declarations 8:7, 8:10, 8:13, 10:5, 11:10, 12:5, 43:12, 51:3	define 18:6, 21:3, 23:4, 34:4, 34:19, 35:3, 37:10, 40:6, 40:22, 41:14, 42:15 defined 13:13, 13:18, 14:5, 17:14, 20:13, 25:11, 25:18, 26:2, 44:1, 44:6, 44:13, 45:16, 45:19, 46:22, 47:2, 47:6, 55:21, 70:5, 70:7, 70:12 defines 13:21 defining 16:18, 16:20, 18:10, 24:17, 37:3, 38:1, 38:13, 38:16 definition 14:11, 14:20, 14:22, 15:2, 15:11, 15:13, 15:17, 16:2, 18:7, 18:13, 18:14, 18:15, 18:20, 19:15, 19:17, 19:18, 20:3, 21:9, 21:11, 22:1, 22:3, 22:5, 22:8, 22:20, 23:7, 23:16, 23:19, 23:20, 45:11, 45:12, 46:13, 64:8, 69:21, 70:8, 70:15, 70:19, 70:21, 72:5, 72:8 definitions 7:2, 14:3
--	---	--	---

deployed 61:8	49:12, 53:3, 54:18, 55:9	25:12, 25:19, 26:2, 26:5, 34:18, 38:3, 39:3, 41:4, 41:5, 42:3, 44:2, 44:7, 46:12, 47:2, 57:11, 59:15, 59:20, 61:21, 67:15, 70:5, 70:6, 72:11	drew 41:22
deponent 4:3, 74:1	differently 46:3, 46:7, 46:17, 46:19, 47:14, 53:3, 55:9, 55:10	discuss 9:10, 49:5, 57:8	drowning 43:7
depos 3:19, 5:13, 6:5, 7:16	difficulty 64:6	discussed 48:21, 63:11, 63:14	duly 6:9, 76:7
deposing 6:22	directed 24:4, 27:12, 27:20, 29:18, 31:13, 31:20, 32:4, 33:9, 33:15, 33:19, 35:12, 35:17, 36:13, 38:5, 41:7, 41:14, 47:18, 48:12, 49:1, 49:18, 50:14, 51:15, 52:3, 52:10, 52:13, 52:22, 53:9, 53:15, 53:20, 54:3, 54:8, 54:10, 54:11, 54:21, 55:12, 68:16	discussion 73:12, 73:14	during 7:3, 57:9
deposition 1:19, 5:5, 5:10, 8:6, 8:12, 8:13, 8:17, 9:7, 9:9, 10:9, 14:8, 14:14, 14:15, 28:17, 29:6, 57:9, 63:12, 73:2, 73:21, 74:5, 74:6, 76:7, 76:8, 76:9, 76:14, 76:16	directing 52:19	document 10:3, 11:8, 11:12	dwell 38:7
described 24:13, 28:9, 67:1, 71:12, 72:1	director 3:21	documents 7:3	E
describes 33:8, 51:14, 52:2	disagree 61:6	dohme 1:6, 5:6, 5:19, 75:2, 76:13	e 32:15, 34:10, 34:16, 37:10, 38:13
description 4:11, 28:8, 28:12	disclose 63:5	doing 29:2, 54:2	each 14:9, 14:11, 14:20, 14:21, 15:13, 20:7, 20:19, 22:22, 23:5, 45:1, 46:4, 46:21, 55:8, 60:4
design 63:17	disclosed 61:20, 62:4	done 24:3, 65:9, 68:18	early 6:14, 30:10
determine 66:1, 66:14	disclosure 4:23, 8:9, 13:19, 13:21, 14:2, 14:17, 15:18, 16:21, 20:5, 21:1, 21:13, 21:15, 21:21, 22:10, 22:21, 23:8, 24:1, 24:17,	down 53:20, 60:17, 68:22	ease 12:13
diagram 36:4		dr 2:11, 4:4, 5:5, 6:8, 6:13, 9:17, 13:15, 14:8, 14:13, 14:19, 33:7, 37:1, 38:19, 42:11, 51:13, 52:1, 57:6, 58:22, 63:15, 63:16, 63:21, 63:22, 67:1	easier 58:8
dichroism 65:17		drawn 36:7	eellison@sternek- essler 3:11
difference 47:16			eldora 3:10
different 22:10, 26:10, 38:7, 38:8, 46:2, 46:6, 46:10, 46:11, 47:15, 49:9,			electronically 11:16
			elliott 2:27
			elliottchoi@quinn- emanuel 2:28
			ellison 3:10
			else 73:16
			elsewhere 26:22, 71:5

emanuel 2:20, 5:21 employed 76:24 enablement 28:8, 28:11 end 30:14, 31:8, 40:9, 45:7, 50:5, 50:17, 50:21, 70:21 ended 62:13 ends 10:21, 12:21, 51:8 enlarge 28:4 entire 18:6, 19:1, 21:21, 39:6, 71:6, 74:4 entirely 32:18 entirety 38:4 enzymatic 20:14, 25:2, 36:12, 41:8, 45:5, 54:1, 56:6, 56:8, 56:17, 64:15, 65:22 enzymatically 20:8, 20:19, 21:7, 23:1, 23:6, 23:10, 26:6, 33:12, 33:17, 33:20, 35:14, 35:15, 35:18, 35:21, 36:2, 36:10, 39:17, 39:21, 40:1, 44:8, 44:11, 44:16, 44:18, 44:21, 45:9, 45:21, 47:4, 47:18,	48:17, 51:17, 52:6, 52:11, 52:15, 53:1, 53:8, 53:11, 53:20, 54:4, 54:6, 54:9, 54:12, 54:19, 55:2, 55:12, 56:14, 59:12 enzyme 22:12, 66:13, 68:14 errata 74:9, 75:1 essential 15:3 essentially 12:5 etc 27:10 evening 9:2 event 49:16 everybody 73:16 evidence 70:3 ex 60:7 examination 4:5, 6:11 examined 6:10, 74:4 example 38:1 except 74:7 excerpted 14:2, 14:14, 16:1, 16:4, 17:16, 18:1, 19:20, 69:19 excluded 68:19 exclusion 65:13 executive 3:21	exhibit 4:12, 4:15, 4:18, 4:21, 4:23, 10:13, 10:15, 11:9, 11:11, 11:14, 11:22, 12:15, 12:17, 13:4, 13:6, 21:3, 34:5, 34:20, 35:3, 37:11, 38:14, 38:17, 40:7, 41:1, 41:8, 41:15, 42:16, 42:22, 59:15, 59:16, 68:22, 69:6, 69:7, 69:8 exhibits 7:20, 8:2, 17:3, 19:7, 71:16 expect 66:19, 67:8 expedited 73:12 experiment 68:18 explain 29:12, 50:8, 50:10, 54:15 explains 16:22 explanations 7:2 explicitly 20:6, 20:18, 21:6, 22:22, 23:5, 23:9, 23:14 express 27:1 expressed 65:1 expressly 25:11, 25:18, 26:1, 26:5, 44:1, 44:6,	44:13, 45:15, 45:19 extract 60:2 eye 7:10 F fact 27:2, 56:17 factors 62:10 falls 62:19 familiarize 65:8 features 15:3, 31:14 feel 28:22 few 32:12, 66:22, 68:3 filtration 65:20 final 9:18, 9:20, 9:22, 10:4, 10:8, 30:16, 47:11, 73:15 financially 76:26 find 10:12, 11:3, 58:14, 69:2, 70:11 fine 25:17, 29:7, 33:2, 43:19, 58:11, 58:21, 64:5 finish 31:18 first 11:8, 14:9, 14:20, 15:2, 15:14, 18:12, 18:13, 18:17,
---	---	---	--

19:3, 24:7, 30:8, 30:11, 51:9, 53:18 five 9:1 flagged 42:12 flexible 6:15 floor 3:7 focus 9:12, 30:10, 45:4, 50:3 focused 29:4, 53:19 focuses 31:6 fold 30:2, 32:8 folded 25:20, 26:3, 26:4, 26:7, 26:9, 26:13, 26:17, 28:6, 30:1, 32:7, 33:11, 33:16, 33:20, 35:13, 35:19, 35:21, 36:1, 36:8, 36:14, 44:8, 44:11, 44:14, 44:18, 45:17, 45:20, 47:4, 47:7, 52:5, 52:14, 52:21, 53:9, 53:15, 53:16, 53:21, 53:22, 54:1, 54:11, 54:17, 54:20, 55:1, 56:2, 56:13, 56:16, 59:11, 62:9, 64:14, 65:3, 65:7, 65:15, 66:10, 66:14 folder 57:13	folding 27:13, 30:11, 30:12, 31:6, 32:14, 45:4, 47:1, 47:9, 47:13, 49:7, 49:21, 50:3, 50:10, 50:19, 51:1, 53:4, 53:14, 54:3 followed 5:16 following 6:20 follows 6:10, 17:16, 17:17 forget 8:20, 9:3 form 21:17, 22:6, 25:19, 26:2, 26:5, 26:13, 26:18, 27:1, 27:12, 37:20, 38:6, 44:2, 44:14, 45:16, 45:20, 47:3, 62:2, 62:16, 71:2 forming 70:1, 70:3, 72:9, 72:11 forms 24:4, 27:7, 28:6, 39:3, 47:6, 47:7, 68:17 formulate 45:2 forth 76:7 found 27:1, 30:2, 47:3 foundation 18:21, 20:15, 23:11, 24:19,	31:1, 31:15, 37:19, 40:3, 49:3, 67:10, 68:11, 71:3, 72:6 four 13:7, 43:13, 48:13 fourth 30:21, 36:20, 48:16 fox 3:6 front 13:7, 13:13, 45:3, 57:12, 57:18, 58:9 full 15:16, 19:19, 31:4, 69:4, 69:5, 72:4, 72:7 fully 24:1 further 18:6, 19:8, 72:21, 76:12, 76:16, 76:22 G gave 63:20 gel 65:20 general 65:10, 65:12 give 6:20, 10:16, 12:18, 31:9, 40:8, 45:7, 50:5, 62:20, 63:4 given 38:8, 46:8, 49:11, 49:22, 50:17, 50:20, 70:15, 74:6, 76:10 gives 19:5, 46:8	glutamate 64:20 go 14:6, 14:16, 19:22, 34:8, 36:3, 36:16, 36:17, 36:19, 40:18, 54:16, 66:13, 67:10, 72:13, 73:4 goes 18:5, 27:6, 43:16, 51:4 going 6:21, 28:18, 49:4, 52:18, 56:19, 56:22, 59:17, 71:4, 71:6, 71:19, 72:15, 73:2 goldstein 3:6 gonna 9:13, 50:3 good 6:13, 6:14, 25:15, 67:17 great 7:6, 10:19, 73:7, 73:14, 73:15 green 36:11, 52:20 H haddach 3:23 halozyme 1:11, 3:22, 3:23, 5:6, 5:21, 75:2 handy 11:3, 19:21, 42:19 happen 67:7 hard 33:2
--	---	--	--

headed 13:13 header 39:15, 39:19 heading 47:10 hear 43:16 hecht 8:10, 33:7, 37:1, 38:19, 51:13, 52:1 hello 57:7 help 39:5 helps 15:16, 18:15, 36:15, 37:22, 39:1 here 5:4, 7:13, 7:14, 12:13, 18:8, 26:8, 29:8, 39:1, 44:19, 45:4, 46:6, 46:16, 46:17, 46:19, 50:3, 50:16, 52:22, 55:5, 58:4, 59:8, 60:6, 62:12, 63:19, 67:13, 70:15 hereby 74:3, 76:4 herein 18:2, 18:19, 24:8, 24:13, 27:4, 69:14, 71:8, 71:12, 72:2 hereinbefore 76:7 highlighted 14:4, 14:10, 16:6, 36:11, 37:22	highlighter 16:13 highlights 67:2 himes 2:14 honestly 26:20 hopefully 64:11 host 38:22 hotel 1:24, 5:11, 76:18 hour 56:20 hours 9:1, 28:20 huntington 2:21 hyaluronidase 15:7, 17:4, 19:8, 21:4, 27:5, 34:5, 34:21, 35:4, 35:6, 37:4, 37:11, 38:2, 38:14, 38:17, 40:7, 40:12, 41:1, 41:8, 41:15, 42:16, 55:13, 71:17 I id 59:6 ideas 40:17 identified 10:15, 11:22, 12:17, 13:6, 59:16, 64:21 identify 5:14 identity 29:20, 32:6 ii 29:21, 32:3	iii 29:22, 30:20, 32:3 imagine 43:9 important 15:10, 21:20 imposed 62:7 inactivate 68:5 inactive 60:12, 60:21, 61:2, 61:4, 61:10, 61:14, 62:1, 62:11, 62:14, 63:7, 63:20, 66:15, 67:22, 68:15 inc 1:11, 3:22, 5:6, 75:2 include 14:3, 19:10, 24:18, 30:21, 39:16, 39:21, 44:15, 44:20, 47:6, 71:22 included 30:19, 62:15 includes 27:8 independent 46:20 independently 42:4, 46:5, 49:10, 49:14, 55:8 inform 42:2 information 62:21, 63:5 instead 20:21, 30:20 instruction 6:20, 7:4 integrates 46:8	intended 30:21 interested 66:12, 76:25 interesting 42:1, 42:7 interpret 59:8, 59:11 investigated 61:21, 64:19 isolated 21:8, 22:11, 23:13, 23:15, 65:5, 66:5, 68:13, 70:13 isolation 20:6, 20:18, 21:6, 21:10, 21:17, 22:8, 22:22, 23:3, 23:13, 23:21, 24:22, 25:1, 25:3, 25:4, 39:4 issue 57:20, 59:3 issued 9:18 itself 23:14, 67:21 J james 1:19, 4:4, 5:5, 6:8, 74:3, 74:14, 75:3, 75:22, 76:6, 76:17 jeff 5:18 jeffrey 2:9 jkushan@sidley 2:10 job 1:29 josh 3:20 judgment 9:21
--	--	--	---

june 1:21, 4:19, 5:1, 5:9, 74:7, 76:19, 76:31	language 20:22, 21:12, 26:10, 26:11, 34:16, 37:18, 40:20, 41:3, 41:9, 41:18, 44:16, 46:10, 47:15, 49:9, 53:4, 54:15, 55:5, 55:8	36:16 limit 28:16, 29:1 limitation 19:5, 24:18 limited 27:16, 39:22, 55:22, 59:11 line 7:10, 69:16, 70:9, 70:18, 75:5 listed 31:21, 60:20, 74:8 literally 37:16 literature 56:16, 64:14, 66:4 litigation 3:21 little 36:4, 36:11, 60:16 livenote 76:2 llc 1:6, 5:6, 5:19, 75:2, 76:13 llp 2:5, 2:20 long 8:22, 14:4, 17:2, 19:7, 26:20, 71:15 look 60:10 looked 8:8, 8:9, 8:11, 12:2, 27:2 looking 7:17, 36:20, 70:9 looks 69:7 lot 67:18	M ma 2:22 mack 3:20 made 62:9, 64:22, 65:15, 67:4, 67:13 mahan 2:11, 9:3 mainly 45:4 make 21:5, 23:15, 26:21, 29:7, 43:19, 58:8, 62:21, 63:1 making 6:16 malliff 1:31, 6:4, 76:2, 76:29 many 26:20 marked 4:10, 8:1, 10:15, 11:17, 11:18, 11:19, 11:21, 11:22, 12:17, 13:6, 59:16 marking 11:16 marriage 76:23 martin 2:24, 4:5, 5:20, 6:12, 9:16, 10:18, 10:19, 11:1, 11:8, 11:21, 12:6, 13:10, 13:14, 19:12, 22:15, 23:17, 25:5, 28:16, 28:22, 29:7,
K	last 10:2, 34:2, 34:14, 63:11 later 27:10, 31:7 latter 50:19 lauren 2:24, 5:20, 73:9 laurenmartin@qui- nnemanuel 2:25 lawyer 28:2, 56:5 least 18:4, 19:11, 24:10, 24:12, 41:5, 71:10, 71:11, 72:1 led 62:11 left-hand 52:19 legal 28:3, 28:15 leif 8:21 leif's 9:4 length 69:5 less 61:8, 61:11, 68:8, 68:14 let's 16:14, 19:21, 32:20, 34:8,		
keep 11:2, 19:21, 42:18, 68:1 kessler 3:6 key 15:15, 64:20 kingdom 1:27, 76:19 know 12:3, 43:6, 56:10, 62:8, 62:17, 63:19, 65:3, 66:9, 66:17, 66:21, 67:6, 67:17, 67:21 known 56:16, 56:18, 64:13, 64:17, 64:19, 64:22 kushan 2:9, 5:18, 5:22, 7:10, 8:4, 8:20, 9:1, 9:13, 11:18, 12:19, 13:3, 18:21, 20:15, 22:6, 23:11, 24:19, 28:18, 28:21, 29:3, 31:1, 31:15, 37:19, 40:3, 49:3, 56:21, 67:10, 68:11, 71:2, 72:6, 72:22, 73:6, 73:9, 73:18			
L			
labeled 10:13			

29:9, 31:11, 31:16, 38:10, 40:10, 48:3, 49:15, 56:19, 57:5, 58:19, 58:20, 68:20, 72:3, 72:13, 72:20, 73:8, 73:11 materials 7:20, 13:3 matter 5:6, 6:19, 8:14, 9:9, 10:12, 11:4, 11:9, 11:13, 11:14, 12:8, 12:10, 12:16, 13:4, 13:9, 27:14, 28:1, 29:15, 30:9, 37:8, 42:20, 43:21, 44:10, 44:12, 44:21, 45:14, 45:18, 47:5, 47:22, 48:8, 48:10, 48:18, 48:20, 49:7, 49:14, 49:16, 50:5, 50:7, 51:3, 51:7, 51:10, 51:21, 52:9, 52:12, 52:18, 53:14, 55:6, 55:14, 57:15, 58:9, 65:11, 65:12, 76:26 matters 8:8, 10:6, 11:11 maybe 60:16, 63:16, 67:5, 67:17 mc 63:4, 64:7, 68:8, 68:13 mean 17:17, 32:1,	57:17, 62:5, 62:12 meaning 19:19, 24:2, 28:20, 35:2, 53:8 means 26:4 meant 35:14, 38:15, 38:18, 52:17, 53:12, 54:15, 56:9, 62:6 measured 62:8 measurements 65:18 mechanism 64:21, 66:13 media 5:4 meet 8:16, 8:19, 8:22, 29:21, 32:5, 48:13 meeting 9:6 meetings 9:10 merck 1:6, 5:6, 5:19, 60:2, 60:7, 75:2, 76:13 merck's 60:11, 60:15 met 8:20 methionine 66:18 might 61:19, 66:13, 67:20 mind 18:16, 58:8 minimum 66:4 mm-hmm 58:11	modification 24:11, 59:10, 71:11 modifications 19:11, 71:22 modified 13:17, 16:3, 16:8, 16:20, 16:22, 17:3, 17:11, 17:13, 18:2, 18:11, 18:19, 19:4, 20:4, 20:7, 20:13, 20:19, 21:3, 21:9, 21:11, 21:14, 22:3, 22:9, 22:13, 22:20, 23:1, 23:8, 23:9, 23:21, 24:2, 24:8, 24:17, 27:16, 27:20, 27:21, 29:18, 31:13, 31:20, 32:5, 33:10, 33:16, 34:4, 34:20, 35:3, 35:12, 35:17, 35:22, 36:9, 37:3, 37:11, 38:13, 38:16, 38:20, 39:17, 39:22, 40:1, 40:7, 40:22, 41:7, 41:14, 42:16, 47:18, 49:1, 49:18, 50:14, 51:16, 52:4, 52:10, 52:13, 54:10, 55:21, 56:1, 59:5, 59:9, 69:14, 69:21, 70:4, 70:19, 70:21, 71:8, 71:14, 71:16, 71:17, 71:21, 72:5	modify 48:13 modifying 61:3 monday 73:15 more 19:10, 28:20, 33:7, 42:8, 51:13, 52:1, 67:3, 71:22 morning 6:15, 8:3 most 9:5, 63:17, 67:3 move 32:14, 43:7 moved 30:13, 47:10 moving 25:13 much 73:16 multiple 21:15 must 6:22, 53:22 mutant 61:11, 61:22, 66:2, 67:4, 67:8, 67:13 mutants 27:20, 60:12, 60:21, 61:14, 67:1, 68:17 mutated 64:20 mutation 61:10, 61:16, 64:22, 65:15 mutations 42:10 myself 12:2, 63:22, 65:8 N naismith 74:14
--	--	---	--

Transcript of James Naismith, Ph.D.
Conducted on June 13, 2026

88

naismith 1:19, 4:4, 4:12, 4:15, 5:5, 6:8, 6:13, 9:17, 11:10, 13:15, 57:6, 58:22, 74:3, 75:3, 75:22, 76:6, 76:17 name 8:21, 9:4, 75:2, 75:3 names 6:1 native 30:2, 65:19 natively 36:8, 54:17 nearly 32:22 necessary 62:21, 66:9 need 12:1, 18:6, 73:9, 73:16 neutral-active 15:9, 26:14, 26:16, 27:6, 47:3 next 25:7, 32:12, 36:20 no:3 59:6 normally 66:6 nos 1:14 noting 42:14 number 12:3, 13:11, 66:22 numbering 69:4 numbers 5:8, 60:1, 60:3, 60:4,	62:8, 71:19 nw 2:6, 3:7 O objection 18:21, 20:15, 22:6, 23:11, 24:19, 31:1, 31:15, 37:19, 37:20, 40:3, 49:3, 67:10, 68:11, 71:2, 72:6 obligated 6:20 obtained 73:5 obvious 68:4 obviously 56:10, 57:17 occurred 76:17 occurs 15:8, 22:9 offering 28:3 office 1:1, 5:7 offices 76:17 oh 7:19, 32:1, 35:16, 73:11 okay 7:6, 7:15, 7:19, 8:5, 11:2, 11:20, 12:9, 12:10, 12:13, 13:8, 14:16, 15:12, 15:22, 25:17, 29:10, 29:14, 33:5, 34:8, 35:5, 36:16, 39:7, 39:10, 39:11, 42:17, 42:21,	43:8, 43:11, 43:19, 47:20, 48:10, 48:20, 51:2, 58:2, 58:12, 58:13, 58:15, 58:16, 58:22, 59:7, 59:18, 60:7, 60:9, 60:15, 64:7, 65:12, 68:21, 69:8, 70:16, 73:1 once 50:18 one 10:21, 11:5, 12:18, 17:17, 19:10, 19:11, 24:10, 24:12, 28:4, 42:11, 60:5, 60:6, 60:20, 60:21, 62:10, 62:17, 66:17, 67:2, 67:3, 69:3, 69:18, 69:22, 70:11, 71:10, 71:11, 71:22, 72:1, 72:8, 73:13 ones 11:5, 35:20, 36:14, 42:11 online 9:3, 9:4, 9:10 only 9:6, 20:21, 28:3, 54:4, 55:1 open 7:11 opinion 20:20, 21:7, 22:13, 24:21, 25:3, 27:17, 28:3, 28:11, 38:3, 41:6, 41:16, 47:11, 70:1, 70:3,	72:9, 72:12 opinions 28:7, 28:8, 28:12, 31:3, 39:3, 45:2 opposite 7:8 order 6:19, 73:9 orders 73:5 orient 60:10 other 15:10, 17:17, 19:9, 28:10, 42:2, 62:10, 62:17, 65:7, 65:18, 66:17, 71:22 otherwise 76:26 ourselves 60:10 out 12:14, 15:11, 20:21, 21:18, 27:17, 27:22, 30:10, 31:3, 32:11, 32:15, 32:18, 38:22, 40:5, 40:19, 42:5, 42:9, 42:13, 46:19, 47:9, 49:5, 49:7, 50:4, 53:4, 54:13, 57:22, 59:5, 68:6, 69:3, 72:8, 72:10 outcome 76:26 over 17:21, 43:16, 48:5, 51:4, 56:19 own 7:1, 8:12,
--	--	---	---

21:17, 22:10, 23:4, 23:20, 46:5, 62:7 owner 1:12, 2:18, 3:4 oxl 1:26, 76:18 oxford 1:26, 5:11, 9:2, 76:18	paragraphs 14:2, 14:5, 21:20, 30:11, 31:5, 32:12, 38:7, 39:14, 40:17, 45:6, 46:1, 49:12, 69:18 parameters 29:21, 32:6 part 16:4, 31:6, 39:2, 39:3, 47:8, 70:3, 71:7 participants 5:17 particular 30:18, 37:22, 38:1, 66:12 particularly 8:10, 38:19, 42:1, 42:12 parties 76:23, 76:24 parts 15:10 party 76:12 passage 37:2, 37:22, 38:12 patent 1:1, 1:3, 1:12, 1:14, 2:18, 3:4, 3:21, 4:13, 4:16, 4:18, 4:19, 4:21, 4:22, 5:7, 6:18, 8:14, 10:14, 10:21, 11:5, 12:4, 12:14, 13:2, 15:6, 21:18, 26:11, 27:15, 28:14, 30:18, 39:6, 41:21, 42:20, 43:2, 45:3, 45:5, 45:11,	45:12, 45:15, 45:19, 46:21, 49:6, 49:13, 55:8, 57:16, 58:3, 58:6, 58:12, 59:3, 59:9, 59:17, 61:1, 61:3, 61:7, 61:13, 61:16, 61:17, 62:7, 62:19, 62:20, 63:4, 63:8, 67:14, 67:15, 69:4, 70:12 patent's 67:15 patents 8:8, 46:3, 46:11, 46:12 pause 42:19, 58:16, 60:7 people 6:1, 64:20, 65:17, 65:18, 66:1, 66:12 perfect 13:1, 13:8, 16:15, 33:5, 39:10, 43:11, 48:7, 48:10, 57:14, 59:2, 69:8, 69:11, 69:12, 72:20 person 2:9, 3:18, 33:3 petitioner 1:7, 2:3, 60:2, 60:7, 76:13 petsko 8:11, 42:11, 63:15, 63:22, 67:1 pgr 1:14, 1:15, 1:16, 4:13, 4:16, 5:8,	10:21, 43:2, 43:10, 43:15 pgrs 9:19 phrase 16:18, 16:20, 17:13, 18:9, 18:11, 21:6, 21:8, 21:14, 21:16, 22:8, 22:11, 23:3, 23:13, 23:15, 39:4, 41:10, 44:20, 70:13 phrasing 39:1 phs 21:3, 33:16, 33:20, 34:4, 34:20, 35:3, 40:7, 41:7, 41:14, 42:16 piece 57:18 place 5:10 places 22:10, 69:22, 70:11 planet 3:19, 5:13, 6:5, 7:16 please 5:14, 6:6, 10:12, 11:2, 11:3, 13:8, 25:6, 29:10, 59:20, 68:21, 70:20, 73:8 pllc 3:6 point 21:5, 21:16, 23:12, 30:8, 31:7, 36:3, 56:15 pointed 20:21, 68:6,
P			
page 4:3, 4:11, 10:2, 13:11, 13:12, 14:1, 14:7, 14:16, 16:1, 19:21, 19:22, 24:5, 25:7, 27:3, 29:8, 29:11, 32:21, 36:4, 36:5, 36:18, 36:20, 39:7, 39:8, 43:15, 43:17, 48:5, 48:6, 51:4, 51:5, 51:8, 54:16, 58:6, 58:7, 58:15, 59:8, 59:15, 59:20, 59:22, 60:3, 60:4, 60:8, 60:11, 60:16, 60:17, 68:22, 69:7, 69:8, 69:11, 70:10, 75:5 pages 15:20, 32:22, 69:2 panel 55:18, 56:4 paper 25:15, 43:7, 63:17, 64:18, 65:8 papers 43:13, 65:18			

72:10 points 38:8 polypeptide 13:18, 16:3, 16:8, 16:21, 17:3, 17:11, 17:14, 18:3, 18:4, 18:11, 18:19, 19:5, 20:4, 20:7, 20:13, 20:19, 21:10, 21:11, 21:14, 22:9, 22:14, 22:21, 23:1, 23:8, 23:21, 24:9, 24:10, 24:15, 24:17, 38:20, 69:15, 69:21, 70:4, 70:19, 70:22, 71:8, 71:9, 71:10, 71:14, 71:16, 71:18, 71:21, 72:5 polypeptides 23:10, 24:3, 29:18, 31:14, 31:20, 32:5, 33:10, 35:12, 35:17, 35:22, 36:9, 37:4, 37:11, 38:14, 38:17, 39:17, 39:22, 40:1, 40:22, 47:19, 48:13, 49:1, 49:18, 50:14, 51:16, 52:4, 52:11, 52:14, 53:10, 54:17, 56:1, 59:10 population 35:20 portion 14:15, 22:2, 53:1, 70:17	portions 14:17 posa 25:19, 26:3, 30:16, 31:10, 33:8, 34:3, 34:14, 34:15, 40:21, 41:6, 44:3, 44:14, 45:16, 45:20, 51:14, 52:2, 52:12, 63:9, 63:15, 63:22 posas 63:18, 64:8 position 29:21, 32:6, 42:10, 57:20, 57:21, 57:22, 59:3, 59:5, 59:10, 60:17, 61:3, 61:9, 61:17, 62:18, 66:18, 66:21, 68:3 positions 67:4 possible 56:12 powers 3:12 precise 65:22 prefix 50:22 prepare 8:5, 8:16, 9:7 preparing 10:5, 10:9 present 3:16, 7:6 presented 7:3 prevent 68:2 previous 8:13, 21:20 previously 4:10, 10:15,	11:22, 12:17, 13:6, 38:20, 59:16, 68:6 priority 64:17 privileged 9:14 probably 5:22 proceed 6:7 proceeding 55:19 produced 30:14 properly 26:12, 26:17, 28:9, 33:11, 33:16, 33:20, 35:13, 35:19, 35:21, 42:3, 52:5, 52:14, 52:21, 53:9, 54:20, 59:11, 65:14, 66:14 protein 24:4, 26:6, 27:12, 28:6, 30:3, 38:6, 62:2, 62:9, 62:11, 62:16, 64:1, 64:2, 64:9, 65:12, 66:5, 66:9, 66:15, 66:20, 67:1, 68:15 proteins 16:22, 45:9, 52:20, 53:16, 54:1, 59:12, 66:5 provided 7:15, 8:3, 13:3 provides 69:20 publications 65:16, 66:16 pull 10:17, 12:14,	42:19 purification 66:7 purified 65:1, 65:13 put 26:18, 58:9, 59:17 Q qrr2 1:31, 76:30 qualified 76:3 question 17:22, 21:22, 28:19, 31:18, 67:17 questions 7:2, 29:4, 72:21, 72:22 quick 56:20, 72:14 quinn 2:20, 5:21 quite 27:18, 66:21, 67:21, 68:3 R randolph 1:24, 5:11, 76:18 rather 7:1 reach 40:18, 46:17 reached 55:10 reaching 40:8 read 6:21, 9:22, 10:2, 10:3, 15:1, 15:14, 15:15, 18:6, 19:1, 19:18, 21:17, 21:21,
---	---	---	--

23:22, 24:21, 27:11, 27:19, 28:13, 28:14, 29:17, 30:15, 30:17, 31:12, 31:19, 32:17, 33:8, 34:3, 37:7, 38:3, 38:18, 38:21, 40:14, 41:4, 41:16, 41:20, 41:21, 42:2, 42:3, 45:8, 47:12, 48:12, 48:22, 49:10, 49:22, 50:13, 51:14, 52:2, 52:12, 52:17, 53:14, 54:9, 55:9, 59:13, 70:1, 70:2, 70:14, 70:17, 71:4, 71:6, 72:4, 72:7, 72:10, 72:11, 72:12, 74:4 reading 32:4, 38:12, 38:15, 39:2, 40:11, 49:13, 54:13, 68:16, 70:20 reads 52:17 realize 6:14 really 6:17 realtime 76:4 reason 67:5, 68:4 reasons 21:18, 38:22, 40:8, 61:19, 62:3 recognize 20:3	record 5:3, 56:22, 57:3, 70:17, 72:14, 72:15, 72:18, 73:2, 73:4, 73:5, 73:12, 73:14, 76:10 reduced 68:1 reductant 68:1 refer 41:18 reference 12:13, 24:14, 59:6, 71:13 referred 24:2 referring 21:13, 36:9 refers 15:7, 18:3, 24:9, 27:4, 71:9 regarding 24:18 regards 28:11 related 76:22 relates 26:11 relevant 14:14 relied 70:2 rely 24:22 remember 9:4, 26:21, 42:8, 42:9 remembering 63:13 remove 58:9 rendered 33:22, 55:10 rendering 47:11	replacement 19:11, 24:12, 71:12, 72:1 replacements 16:10, 17:2, 17:12, 19:7, 19:9, 19:14, 71:15, 71:20 report 26:20, 46:3, 46:4, 46:7, 47:14 reporter 1:30, 6:4, 6:6, 7:9, 11:7, 11:15, 11:19, 26:15, 48:2, 73:4, 73:19, 76:1, 76:3, 76:4 represent 5:15 represented 76:13 representing 5:19, 5:21 require 20:13, 27:11, 35:6, 40:12, 47:1 required 25:2 requirement 22:12, 29:22, 48:16 requirements 48:14, 49:19 requires 38:21, 59:9 requiring 37:4 reread 8:7 residue 64:20 respectful 56:10 respective 11:11	rest 6:1, 39:5 result 66:19 resulting 17:2, 71:16 results 61:4 reveal 9:14 right 6:18, 7:7, 7:9, 7:10, 13:17, 13:20, 14:3, 14:12, 16:11, 16:14, 18:12, 18:20, 19:15, 26:9, 28:2, 30:6, 32:8, 33:13, 33:17, 34:22, 37:8, 39:12, 39:18, 40:2, 43:20, 45:14, 46:13, 48:14, 50:11, 52:7, 52:8, 52:15, 53:11, 57:11, 57:12, 59:14, 60:2, 60:5, 61:12, 63:13, 72:13 right-hand 60:17 robust 68:13 romanette 30:21 romanettes 30:19, 31:21, 32:1 room 5:16, 7:7 rough 73:6 S said 13:20, 14:7,
---	--	---	---

Transcript of James Naismith, Ph.D.
Conducted on June 13, 2026

92

15:14, 19:1, 19:13, 19:16, 20:17, 21:11, 21:20, 22:4, 23:2, 23:16, 34:1, 35:10, 37:16, 38:11, 39:9, 39:10, 41:2, 44:22, 45:6, 45:15, 45:19, 46:10, 46:14, 47:6, 47:8, 51:19, 52:16, 53:7, 56:4, 62:3, 63:1, 63:15, 63:17, 63:19, 64:13, 64:16, 66:11, 67:14, 70:12, 71:5 same 10:20, 12:5, 29:8, 30:1, 32:7, 42:19, 45:10, 45:12, 46:12, 46:13, 46:15, 46:17, 55:5, 59:8, 64:6, 69:11 satisfies 29:20 satisfy 31:14, 31:21, 49:1, 49:19, 50:15, 61:18, 68:9 saturday 1:21, 5:1, 6:17, 74:7, 76:19 save 74:7 say 7:18, 8:14, 16:19, 17:15, 17:20, 17:22, 20:2, 21:9, 22:16, 25:2,	29:15, 30:5, 31:12, 31:18, 33:6, 34:9, 34:14, 35:14, 38:15, 39:15, 40:5, 40:15, 41:2, 41:13, 43:21, 44:9, 44:10, 44:12, 44:15, 48:11, 48:21, 49:5, 49:17, 50:7, 50:16, 51:12, 51:22, 52:9, 52:12, 54:5, 54:6, 55:17, 56:6, 66:8, 66:11, 68:12 saying 15:12, 30:20, 31:2, 31:3, 33:19, 35:5, 35:8, 37:14, 37:17, 37:21, 53:7, 53:13, 54:2 says 17:10, 18:16, 19:6, 20:11, 22:17, 25:22, 31:10, 32:15, 33:14, 35:1, 35:9, 35:19, 39:20, 40:12, 48:18, 54:22, 59:4, 60:2, 60:13, 69:5, 69:13 scanned 8:12 science 65:16, 67:7 scientific 28:4, 56:15 scope 9:11, 28:1, 28:5, 28:13, 28:16, 41:17,	49:11, 62:15, 62:19, 63:10, 64:9 screen 10:18, 25:13, 25:16, 58:19 scroll 25:14 sds-page 65:20 sea 43:7 second 8:21, 9:4, 10:16, 11:12, 16:6, 16:15, 55:17, 60:6 second-to-last 58:7, 58:15 secreted 62:9, 65:6 section 50:1, 50:19, 50:21, 59:1 sections 30:18, 50:11, 53:18 see 12:1, 16:15, 32:1, 35:16, 36:3, 36:21, 37:5, 37:6, 43:6, 51:9, 51:19, 60:11, 60:13, 60:16, 63:9, 65:17, 66:3, 66:15, 68:4, 69:12 send 73:6 sentence 14:9, 14:20, 15:3, 15:14, 16:6, 16:13, 16:16, 17:9, 17:13, 17:16, 18:12, 18:14, 18:18, 19:3,	19:14, 19:17, 20:10, 22:16, 22:17, 22:18, 24:7, 24:22, 25:1, 25:4, 25:10, 25:22, 26:19, 30:8, 33:14, 34:2, 34:6, 34:14, 35:1, 36:20, 36:21, 37:6, 41:19, 42:6, 43:22, 44:5, 49:20, 50:2, 51:9, 52:17, 54:10, 54:22, 55:17, 56:7, 56:8, 70:14 sep 4:22 separate 32:15, 50:4 separated 30:10, 47:9, 49:7, 53:4, 53:13 separately 45:2 seq 59:6 sequence 24:13, 29:19, 29:20, 32:6, 69:5, 71:12 series 31:5, 39:13 set 21:3, 21:18, 27:17, 27:22, 30:17, 31:3, 32:10, 32:17, 34:4, 34:20, 35:3, 38:22, 40:6, 40:22, 41:14, 42:15, 49:5, 72:8, 76:7 share 58:18
---	---	---	---

sharp 1:6, 5:6, 5:19, 75:2, 76:13 sheet 74:9, 75:1 short 57:2, 72:17 should 9:12, 11:5, 13:2, 28:14, 28:19, 28:20, 29:1, 58:6, 72:10 shown 36:8 sic 16:9, 17:12, 50:18 side 58:10 side-by-side 43:12 sidley 2:5, 5:18, 8:21 signature-plkal 76:27 signed 74:13 simple 65:19 simply 21:16, 22:13 simpson 8:10, 14:8, 14:13, 14:19, 63:21, 64:18 simpson's 63:16 since 28:7, 63:7, 68:15 single 21:8, 65:15 site 65:16 size 65:13 slip 67:22	solely 20:20, 25:4 solution 68:1 some 9:18, 43:7 somebody 7:16 sometimes 65:17, 65:22, 66:15, 67:19, 67:22, 68:5 somewhere 58:3 sorry 17:21, 23:5, 23:19, 25:13, 31:17, 32:3, 33:2, 34:12, 34:13, 35:16, 36:3, 36:14, 36:19, 40:11, 44:4, 47:7, 50:21, 55:21, 58:14, 59:21, 60:6, 63:3, 64:3, 64:7 sort 63:16 specific 42:9, 52:19 specifically 42:9 specification 16:2, 47:1 spell 40:5, 40:18 spells 59:5 spelt 15:11, 46:19 spent 9:1 sperm 15:8, 26:14, 27:2, 27:6 split 30:17, 44:22,	45:3, 47:13 splits 43:17, 48:5 stability 36:12 stable 54:20, 56:13 stably 36:10, 56:2, 56:13, 56:16, 64:14, 65:3, 66:10 stages 30:11 stand 46:5 standing 6:19 start 22:18, 25:14, 25:17, 28:18, 31:17, 34:13, 49:5, 50:11, 70:20 starting 32:22, 70:9, 70:18 starts 16:7, 17:9, 32:20, 36:22 state 5:15, 20:6, 20:12, 20:16, 20:18, 21:7, 22:22, 23:5, 23:9, 23:14, 25:2, 25:9, 25:10, 27:11, 30:2, 41:12 stated 14:13, 17:8, 27:18, 37:8, 38:20 statement 24:16 states 1:1, 5:7, 49:21 sterne 3:6	stick 67:21 still 50:12, 53:6, 62:13 stop 70:20 street 1:25, 2:6, 3:7, 5:11, 76:18 strike 25:13 structure 66:1, 66:8, 66:14 studies 65:22 sub-categories 53:17 sub-populations 36:8 subscribed 75:18 subsection 39:11, 39:16 subsections 50:8 subset 28:10, 30:12, 36:1, 36:14, 54:3 subsets 28:10 substance 57:8 substitution 29:22, 32:7 substitutions 42:13 subtleties 66:13 suite 2:21 sullivan 2:20 summers 2:29 supports 37:2, 38:12,
--	--	---	---

Transcript of James Naismith, Ph.D.
Conducted on June 13, 2026

94

38:15 sure 12:20, 29:7, 43:20, 56:21, 60:5, 63:1, 69:1 surface 26:13, 27:1, 47:3 surprised 67:7 surprises 67:7 suspect 67:5, 67:16 swear 6:6 sworn 4:4, 6:9, 75:18, 76:7 T table 60:11, 60:14, 62:14 take 56:20, 72:14 taken 76:9 taking 5:10 talk 17:21, 32:12 talked 7:21, 14:5, 63:14 talking 19:4, 22:3, 22:7, 28:18, 46:15, 57:14 talks 50:2 taught 61:17 teaches 61:3, 61:7 tech 42:22 technician 10:17, 11:15,	13:10, 58:18 tell 6:9, 19:9, 33:2, 63:6 tells 19:2, 19:3 tend 66:6 tends 63:15 term 14:11, 20:12, 70:5 terms 13:13, 13:17, 13:21, 14:21, 15:13, 17:15, 63:8 tertiary 30:1, 32:8 test 42:4, 45:1, 66:16 testified 6:10, 14:8 testimony 27:14, 46:22, 74:6, 76:10 tests 65:7 text 69:4 th 3:7 thank 6:15, 6:16, 12:20, 43:4, 44:9, 48:4, 58:21, 59:7, 64:10, 64:12, 73:19, 73:20 thanks 73:15 themselves 5:15 therefore 64:9, 65:6 thereof 27:7	thing 8:15 things 13:7, 26:20, 28:9, 30:12, 43:8, 65:9, 66:3, 68:5, 71:7, 72:9 think 8:13, 9:3, 10:2, 12:7, 12:8, 13:22, 14:13, 14:22, 18:17, 19:1, 19:16, 25:7, 28:5, 36:4, 36:13, 36:19, 39:9, 42:11, 47:15, 51:1, 61:6, 62:3, 63:15, 63:21, 64:19, 67:2, 67:5, 67:18, 69:18 third 25:9, 43:22 thought 42:7, 42:14, 46:19, 67:18 three 8:7, 12:18, 31:14, 31:21, 49:2, 49:19, 50:15 threshold 28:15, 62:7, 63:12, 66:4, 66:16, 67:9 through 8:8, 8:11, 8:12, 10:3, 15:15, 30:19 time 5:9, 9:5, 42:19, 57:1, 57:4, 69:3, 72:16, 72:19, 73:2	times 21:15 timing 9:11, 73:10 today 5:12, 6:4, 8:6, 10:10 today's 5:9 told 9:8 tolerant 42:12 tolerate 68:3 tolerated 67:3 tolerates 66:21 top 36:5, 52:19, 69:5 touched 8:4 tpowers@sterneke-ssler 3:13 trademark 1:1, 5:7 transcript 64:6, 74:4 transcription 74:6 tray 3:12 trial 1:3, 6:18 tricky 67:19 tried 54:14 true 74:5, 76:9 truncated 27:7 truth 6:9 trying 53:6, 65:10
--	--	--	--

tubes 67:21 turn 13:8, 15:19, 16:14, 24:5, 25:6, 29:10, 32:20, 39:7, 42:17, 43:5, 43:14, 43:16, 47:20, 48:7, 51:2, 55:14, 57:18, 58:5, 59:14, 60:15, 68:21, 69:2 turning 51:7 two 13:21, 14:4, 30:18, 43:11, 43:12, 43:18, 48:9, 49:12, 60:4 type 15:7, 27:4 types 54:18 typically 71:17 U uk 5:11 um 8:12 under 6:18, 13:22, 61:15, 61:20, 62:4, 67:9, 68:9 underlying 40:17 understand 7:4, 12:4, 18:7, 18:15, 19:19, 22:11, 24:1, 25:19, 26:3, 27:22, 28:12, 32:9, 34:9, 35:11,	37:22, 39:2, 44:3, 44:7, 44:14, 45:16, 45:20, 46:4, 53:6, 55:18, 61:9, 65:10 understanding 23:20, 24:20, 25:3, 30:12, 31:4, 41:20, 46:20, 55:7 understood 12:10, 21:18, 23:22, 26:13, 26:17, 71:21 unexpected 68:6 unfold 68:5 unfolded 66:5, 66:20, 67:6 united 1:1, 1:27, 5:7, 76:18 universe 36:7, 52:21, 53:1 unmodified 24:15, 71:13 urquhart 2:20 use 17:19, 21:16, 23:15, 25:15, 26:8, 26:9, 37:17, 42:1, 46:1, 55:5, 60:1, 63:18 uses 63:17 V variant 60:21, 61:1, 61:18, 62:18, 68:8, 71:9 variants 27:9, 56:15,	64:13 variety 66:3 various 36:7 vc 10:17, 13:10, 58:18 via 2:11, 2:14, 2:18, 3:4, 3:20, 3:23 video 1:19, 5:10 videographer 3:19, 5:4, 5:12, 6:3, 7:8, 56:22, 57:3, 72:15, 72:18, 73:1, 73:20 videotaped 5:5 viner 3:18, 5:12 visible 43:14 W want 13:1, 17:20, 17:21, 34:8, 43:19, 57:17, 58:21, 60:1, 60:5, 63:1, 64:18, 69:3 washington 2:7, 3:8 waste 69:3 way 46:5, 62:17, 66:17, 76:25 ways 60:17 we're 10:20, 29:8, 34:12, 43:20, 52:18, 59:7,	63:2, 69:11 we've 7:21, 36:7, 56:19, 57:14 welcome 57:6 well-performed 68:13 wendy 3:18, 5:12 went 71:7, 72:9 whatever 70:17, 73:12 whereupon 73:21 whether 62:18, 63:6, 66:9, 66:17, 67:12, 67:18 whole 15:1, 19:18, 19:20, 21:2, 29:17, 30:15, 31:13, 31:19, 32:4, 33:9, 35:11, 38:22, 48:12, 48:22, 49:17, 50:13, 51:15, 52:3, 52:10, 52:13, 53:9, 72:11 wild-type 30:3 wise 73:10 within 28:5, 35:20, 53:17, 54:3, 54:17, 62:15, 62:19, 63:9, 70:6 witness 6:7, 9:13, 12:1, 13:12, 18:22, 20:16, 22:7, 23:12, 24:20, 28:18,
---	--	--	---

Transcript of James Naismith, Ph.D.
Conducted on June 13, 2026

96

31:2, 37:21, 40:4, 49:4, 67:12, 68:12, 71:4, 72:7, 75:3, 76:6, 76:10 word 22:1, 22:4, 26:8, 26:9, 26:18, 26:21 words 7:2, 17:6, 22:13, 37:16, 44:17, 46:2, 47:17, 49:12 worries 6:3, 6:16 worth 42:14 wouldn't 28:10, 63:18 written 9:18, 9:22, 10:5, 10:9, 17:6, 28:7, 28:11, 34:6, 34:11 wrong 8:15, 19:15, 19:16 wrote 17:8, 22:18, 41:21, 46:7, 68:22 Y yeah 7:18, 10:19, 12:7, 12:9, 17:6, 34:13, 39:10, 41:11, 43:19, 44:5, 47:8, 58:21, 60:14, 73:11 yellow 14:10, 16:12 yesterday 9:2	yourself 6:16 Z zach 2:29 zachsummers@quin- nemanuel 2:30 zoom 2:11, 2:14, 2:18, 3:4, 3:20, 3:23, 5:16, 6:2, 7:12, 9:10 . .10 4:12 .11 4:15 .12 4:18 .13 4:21 .59 4:23 .6 4:4, 4:5 0 00004 4:13, 10:21, 43:2, 43:10, 43:15 00042 1:14 00046 1:15, 4:16 00052 1:16 0042 5:8 0046 5:8, 44:17 0052 5:8 02199 2:22	06 57:4 1 1 57:1 10 3:7, 63:16, 63:19 100 15:19, 15:21, 15:22, 16:9, 16:15, 16:16, 17:11, 36:17, 36:21 1001 4:18, 4:21, 12:15, 12:17, 13:4, 13:6 1026 4:23, 59:15, 59:16, 60:7, 68:22 104 25:6, 25:9, 26:19, 30:13, 42:18, 43:5, 43:10, 43:12, 43:14, 43:15, 43:21, 47:10 105 45:6 108 30:13, 30:15, 31:9, 32:19, 32:20, 33:4, 33:5, 34:7, 35:10, 39:1, 50:17, 50:21, 51:2, 53:2, 54:5 109 19:22, 20:2, 20:12, 21:5, 21:12, 22:1, 22:5, 22:19, 34:1, 34:2, 34:11, 34:12, 34:14, 38:4,	40:14, 40:16, 40:19, 41:2, 45:6, 45:7, 46:8, 49:11, 50:1, 50:6, 50:21, 55:11 110 28:1, 55:14 1101 3:7 111 2:21 112 28:19, 28:20 1133 4:12, 4:15, 10:15, 11:9, 11:11, 11:14, 11:22 12 1:22, 5:3, 5:10, 76:19 12,018,298 4:14, 4:18 12,037,618 1:14 12,091,692 1:15, 4:17, 4:21 12,264,345 1:16 13 1:21, 5:1, 5:9, 74:7, 76:19 135 59:15, 59:22 14 76:31 145 60:11 148 60:8, 60:16 150 17:1, 19:6, 19:14, 71:15 1501 2:6 17 4:22
---	--	--	--

Transcript of James Naismith, Ph.D.
Conducted on June 13, 2026

97

185 58:6 19 29:11, 48:5, 61:22, 62:1, 62:9, 62:13, 62:14, 63:7, 63:8, 63:21, 64:7 2 2 57:4, 72:16, 72:19, 73:3, 73:21, 76:20 20005 2:7, 3:8 202 2:8, 3:9 2024 4:19, 4:22 2025 1:14, 1:15, 1:16, 4:13, 4:16, 5:8, 10:21, 43:2, 43:10, 43:15 2026 1:21, 5:1, 5:9, 74:7, 74:18, 75:19, 76:19, 76:31 25 4:19 28 72:16 298 10:13, 10:21, 12:4, 12:14, 12:22, 42:20, 43:2, 45:11, 45:18, 47:15, 47:16, 47:21 21n 1:26, 76:18 3 313 29:22, 32:7,	42:11, 57:21, 58:1, 59:3, 59:5, 59:10, 60:17, 61:1, 61:4, 61:7, 61:9, 61:17, 62:12, 62:18, 62:21, 63:1, 63:2, 63:4, 64:7, 66:18, 68:8, 68:13 33 72:19, 73:3 35 73:21, 76:20 4 41 1:22, 5:3, 5:10, 76:19 42 10:6 43 29:10, 29:11, 29:14, 30:7, 30:11, 30:20, 31:12, 31:19, 47:20, 48:3, 48:8, 48:11, 48:21, 49:16, 50:7, 50:13 46 10:6, 11:4, 11:13, 11:14, 12:11, 13:4, 13:9, 27:15, 29:15, 37:9, 44:12, 44:21, 45:5, 45:14, 47:5, 47:17, 48:8, 48:20, 49:7, 49:17, 50:7, 51:3, 51:4, 51:21, 52:12, 52:18, 53:14, 55:15, 57:15 48 30:11	49 36:4, 36:5, 54:16 5 5 34:10, 34:17, 37:10, 38:13 50 71:20 52 10:6, 57:1 520 2:21 57 13:12 58 14:1, 14:16, 27:3 59 14:7 6 600 8:14, 12:3, 12:7 617 2:23 638140 1:29 65 15:20, 36:18 66 15:20, 16:1, 19:21, 24:5 67 43:16, 68:22, 69:4, 69:7, 69:8, 70:10 68 25:7, 43:16 69 39:7, 39:8 692 11:4, 13:2, 27:15, 45:11, 45:15, 57:16, 57:18, 58:2,	58:5, 58:12, 59:2, 59:9, 59:17, 61:16, 62:19 7 70 51:8 71 32:21, 51:4 7100 2:23 712 2:23 73 51:5, 51:8 736 2:8 74 19:22 772 3:9 8 8508 3:9 8914 2:8 9 90 13:9, 13:15, 14:1 91 14:6 95 69:9 96 69:9 97 69:9 98 69:9 99 69:9
---	--	--	---